[
  {
    "id": "41438577",
    "title_en": "Sulforaphane-cysteine elicits apoptosis through JNK-mediated caspase activation in oral squamous cell carcinoma cells.",
    "pub_date": "2026",
    "journal": "Journal of Cancer",
    "abstract_en": "Sulforaphane-cysteine (SFN-Cys) is a naturally-occurring form of plant-derived isothiocyanate metabolites that displays several tumor-suppressive properties. However, the oncostatic potential of SFN-Cys on oral squamous cell carcinoma (OSCC) is mostly elusive. In this study, we tried to test whether SFN-Cys affects OSCC to progress and further explored the underlying array of molecular cues that SFN-Cys mediates. Our results demonstrate that SFN-Cys was an effective inducer of cytotoxicity to OSCC cells, accompanied with blockage of cell cycling and promotion of apoptotic events. Moreover, treatment of OSCC cells with SFN-Cys attuned an apoptosis-associated protein regulatory program, underlined by downregulation of apoptosis suppressors (cIAP-1 and XIAP) and activation of caspase cascades. Furthermore, caspase activations in SFN-Cys-treated OSCC cells were affected by the pre-incubation with a specific c-Jun N-terminal kinase (JNK) inhibitor, suggesting a functional link of JNK pathway to SFN-Cys's actions in OSCC cells. Collectively, our data revealed that SFN-Cys hampered cell cycle progression and elicited apoptotic responses in OSCC via a JNK-mediated activation of caspase pathways. These findings provide possible avenues for the application of a natural compound in the management of oral malignancies.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é¡¯ç¤ºå‡ºå°è…«ç˜¤ç´°èƒçš„æŠ‘åˆ¶ä½œç”¨ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å£è…”é±—ç‹€ç´°èƒç™Œçš„ä¸€å€‹æ½›åœ¨é¸æ“‡ã€‚éš¨è‘—å°é€™é¡ç™Œç—‡çš„æ²»ç™‚éœ€æ±‚æ—¥ç›Šå¢åŠ ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„å¤©ç„¶ç™‚æ³•å°‡æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œï¼Œä¸¦å¯èƒ½æ¸›å°‘å‚³çµ±æ²»ç™‚æ–¹æ³•çš„å‰¯ä½œç”¨ã€‚é€™é …ç ”ç©¶æä¾›äº†é€²ä¸€æ­¥æ¢ç´¢å¤©ç„¶åŒ–åˆç‰©åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„åŸºç¤ï¼Œå°¤å…¶æ˜¯åœ¨å£è…”ç™Œé€™ä¸€é ˜åŸŸã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯SFN-Cysæ˜¯å¦èƒ½å¤ æŠ‘åˆ¶é€™ç¨®ç™Œç—‡çš„é€²å±•ï¼Œä»¥åŠå®ƒåœ¨ç´°èƒå±¤é¢ä¸Šå¦‚ä½•ç™¼æ®ä½œç”¨ã€‚ç”±æ–¼ç›®å‰å°æ–¼SFN-Cysåœ¨å£è…”ç™Œä¸­çš„æ½›åœ¨æŠ—è…«ç˜¤æ•ˆæœäº†è§£ä¸å¤šï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ï¼Œä¸¦æ·±å…¥åˆ†æå…¶å¯èƒ½çš„åˆ†å­æ©Ÿåˆ¶ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒä¾†æ¸¬è©¦SFN-Cysçš„æ•ˆæœã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯ŸSFN-Cyså°ç™Œç´°èƒçš„ç´°èƒæ¯’æ€§å½±éŸ¿ï¼Œä¸¦åˆ†æå…¶å°ç´°èƒé€±æœŸå’Œå‡‹äº¡çš„å½±éŸ¿ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…è©•ä¼°äº†SFN-Cyså¦‚ä½•èª¿ç¯€èˆ‡å‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªï¼Œä¸¦æª¢æŸ¥äº†JNKé€šè·¯åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ å…¨é¢äº†è§£SFN-Cysåœ¨ç™Œç´°èƒä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒSFN-Cysèƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦ä¸”èƒ½å¤ é˜»æ­¢ç´°èƒé€±æœŸçš„é€²è¡Œï¼Œä¿ƒé€²å‡‹äº¡äº‹ä»¶çš„ç™¼ç”Ÿã€‚å…·é«”ä¾†èªªï¼ŒSFN-Cysé™ä½äº†å‡‹äº¡æŠ‘åˆ¶å› å­çš„è¡¨é”ï¼Œä¸¦æ¿€æ´»äº†caspaseç´šè¯åæ‡‰ã€‚æ­¤å¤–ï¼Œç•¶SFN-Cysè™•ç†çš„ç™Œç´°èƒèˆ‡ç‰¹å®šçš„JNKæŠ‘åˆ¶åŠ‘å…±åŒåŸ¹é¤Šæ™‚ï¼Œcaspaseçš„æ´»åŒ–å—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜JNKé€šè·¯åœ¨SFN-Cysçš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºæœªä¾†åœ¨å£è…”æƒ¡æ€§è…«ç˜¤ç®¡ç†ä¸­æ‡‰ç”¨å¤©ç„¶åŒ–åˆç‰©æä¾›äº†å¯èƒ½çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é¡¯ç¤ºå‡ºå°è…«ç˜¤ç´°èƒçš„æŠ‘åˆ¶ä½œç”¨ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å£è…”é±—ç‹€ç´°èƒç™Œçš„ä¸€å€‹æ½›åœ¨é¸æ“‡ã€‚éš¨è‘—å°é€™é¡ç™Œç—‡çš„æ²»ç™‚éœ€æ±‚æ—¥ç›Šå¢åŠ ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„å¤©ç„¶ç™‚æ³•å°‡æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œï¼Œä¸¦å¯èƒ½æ¸›å°‘å‚³çµ±æ²»ç™‚æ–¹æ³•çš„å‰¯ä½œç”¨ã€‚é€™é …ç ”ç©¶æä¾›äº†é€²ä¸€æ­¥æ¢ç´¢å¤©ç„¶åŒ–åˆç‰©åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„åŸºç¤ï¼Œå°¤å…¶æ˜¯åœ¨å£è…”ç™Œé€™ä¸€é ˜åŸŸã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯SFN-Cysæ˜¯å¦èƒ½å¤ æŠ‘åˆ¶é€™ç¨®ç™Œç—‡çš„é€²å±•ï¼Œä»¥åŠå®ƒåœ¨ç´°èƒå±¤é¢ä¸Šå¦‚ä½•ç™¼æ®ä½œç”¨ã€‚ç”±æ–¼ç›®å‰å°æ–¼SFN-Cysåœ¨å£è…”ç™Œä¸­çš„æ½›åœ¨æŠ—è…«ç˜¤æ•ˆæœäº†è§£ä¸å¤šï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ï¼Œä¸¦æ·±å…¥åˆ†æå…¶å¯èƒ½çš„åˆ†å­æ©Ÿåˆ¶ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒä¾†æ¸¬è©¦SFN-Cysçš„æ•ˆæœã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯ŸSFN-Cyså°ç™Œç´°èƒçš„ç´°èƒæ¯’æ€§å½±éŸ¿ï¼Œä¸¦åˆ†æå…¶å°ç´°èƒé€±æœŸå’Œå‡‹äº¡çš„å½±éŸ¿ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…è©•ä¼°äº†SFN-Cyså¦‚ä½•èª¿ç¯€èˆ‡å‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªï¼Œä¸¦æª¢æŸ¥äº†JNKé€šè·¯åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ å…¨é¢äº†è§£SFN-Cysåœ¨ç™Œç´°èƒä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒSFN-Cysèƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦ä¸”èƒ½å¤ é˜»æ­¢ç´°èƒé€±æœŸçš„é€²è¡Œï¼Œä¿ƒé€²å‡‹äº¡äº‹ä»¶çš„ç™¼ç”Ÿã€‚å…·é«”ä¾†èªªï¼ŒSFN-Cysé™ä½äº†å‡‹äº¡æŠ‘åˆ¶å› å­çš„è¡¨é”ï¼Œä¸¦æ¿€æ´»äº†caspaseç´šè¯åæ‡‰ã€‚æ­¤å¤–ï¼Œç•¶SFN-Cysè™•ç†çš„ç™Œç´°èƒèˆ‡ç‰¹å®šçš„JNKæŠ‘åˆ¶åŠ‘å…±åŒåŸ¹é¤Šæ™‚ï¼Œcaspaseçš„æ´»åŒ–å—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜JNKé€šè·¯åœ¨SFN-Cysçš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºæœªä¾†åœ¨å£è…”æƒ¡æ€§è…«ç˜¤ç®¡ç†ä¸­æ‡‰ç”¨å¤©ç„¶åŒ–åˆç‰©æä¾›äº†å¯èƒ½çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of Cancerã€‹æ–¼ 2026 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°å£è…”ç™Œç´°èƒæœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œé€™å¯èƒ½æœƒæˆç‚ºæœªä¾†æ²»ç™‚çš„ä¸€å€‹æ–°é¸æ“‡ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰çš„åŒ–åˆç‰©ï¼Œç ”ç©¶äººå“¡æƒ³çŸ¥é“å®ƒæ˜¯å¦èƒ½æŠ‘åˆ¶å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„é€²å±•ï¼Œä¸¦ä¸”äº†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç‚ºäº†é€²è¡Œé€™é …ç ”ç©¶ï¼Œä»–å€‘ç”¨ç™Œç´°èƒä¾†æ¸¬è©¦SFN-Cysçš„æ•ˆæœï¼ŒåŒ…æ‹¬è§€å¯Ÿå°ç™Œç´°èƒçš„æ¯’æ€§å½±éŸ¿å’Œç´°èƒé€±æœŸçš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼ŒSFN-Cysä¸åƒ…èƒ½å¤ æœ‰æ•ˆèª˜å°ç™Œç´°èƒçš„æ­»äº¡ï¼Œé‚„èƒ½é˜»æ­¢å®ƒå€‘çš„ç”Ÿé•·ã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼Œé€™ç¨®åŒ–åˆç‰©é™ä½äº†æŸäº›æŠ‘åˆ¶ç´°èƒæ­»äº¡çš„å› å­ï¼Œä¸¦æ¿€æ´»äº†ä¿ƒä½¿ç´°èƒæ­»äº¡çš„æ©Ÿåˆ¶ã€‚ç•¶SFN-Cysèˆ‡ç‰¹å®šçš„æŠ‘åˆ¶åŠ‘ä¸€èµ·ä½¿ç”¨æ™‚ï¼Œé€™äº›æ•ˆæœæœƒæœ‰æ‰€è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºå®ƒåœ¨ç´°èƒä¸­çš„ä½œç”¨æ˜¯ç›¸ç•¶è¤‡é›œçš„ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºå£è…”ç™Œæ²»ç™‚çš„æ–°é¸æ“‡ã€‚\n2. SFN-Cysèƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦é˜»æ­¢å…¶ç”Ÿé•·ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†å¤©ç„¶åŒ–åˆç‰©åœ¨ç™Œç—‡ç®¡ç†ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "image_prompt": "Create a simple infographic to explain the experiment and main results of a study on Sulforaphane-Cysteine (SFN-Cys) and its effects on oral squamous cell carcinoma (OSCC). The image should have a light background with soft colors, featuring flat design elements. Include symbols for broccoli or Sulforaphane, simplified representations of experimental subjects (like cells or humans), arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å£è…”é±—ç‹€ç´°èƒç™Œ Oral Squamous Cell Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41438577/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ï¼Œé€™å¯èƒ½å°æ–¼å¸Œæœ›å¢å¼·å…ç–«åŠ›æˆ–æ”¹å–„å¥åº·ç‹€æ³çš„äººå€‘ä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„ç™¼ç¾ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„ç”Ÿç‰©åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›è™•ç†æ–¹æ³•å¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å¾Œçš„ç”¢å“åœ¨åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼ä¸­çš„æ½›åŠ›ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶å°è±¡æ˜¯4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦æ¸¬é‡äº†å…¶è˜¿è””ç¡«ç´ åŠå…¶ä»–ç‡Ÿé¤Šæˆåˆ†çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªï¼ŒåŒ…æ‹¬æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹åˆ†ä¿æŒèƒ½åŠ›ç­‰æŒ‡æ¨™ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡æé«˜äº†316.30%ï¼ŒåŒæ™‚ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥å¾Œçš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†é«˜æ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†å’Œæ²¹åˆ†ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„å”åŒæ‡‰ç”¨åœ¨åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ï¼Œé€™å¯èƒ½å°æ–¼å¸Œæœ›å¢å¼·å…ç–«åŠ›æˆ–æ”¹å–„å¥åº·ç‹€æ³çš„äººå€‘ä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„ç™¼ç¾ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„ç”Ÿç‰©åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›è™•ç†æ–¹æ³•å¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å¾Œçš„ç”¢å“åœ¨åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼ä¸­çš„æ½›åŠ›ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶å°è±¡æ˜¯4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦æ¸¬é‡äº†å…¶è˜¿è””ç¡«ç´ åŠå…¶ä»–ç‡Ÿé¤Šæˆåˆ†çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªï¼ŒåŒ…æ‹¬æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹åˆ†ä¿æŒèƒ½åŠ›ç­‰æŒ‡æ¨™ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡æé«˜äº†316.30%ï¼ŒåŒæ™‚ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥å¾Œçš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†é«˜æ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†å’Œæ²¹åˆ†ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„å”åŒæ‡‰ç”¨åœ¨åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†å—ï¼Ÿå®ƒå°æˆ‘å€‘çš„å¥åº·å¯æœ‰å¹«åŠ©å“¦ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„è˜¿è””ç¡«ç´ å«é‡å¯ä»¥å¤§å¹…æé«˜ï¼Œé€™ä¸åƒ…å¯èƒ½å¢å¼·æˆ‘å€‘çš„å…ç–«åŠ›ï¼Œé‚„èƒ½å¹«åŠ©é é˜²ä¸€äº›ç–¾ç—…ï¼\n\né€™é …ç ”ç©¶çš„é‡é»æ˜¯ç ”ç©¶ä¸€ç¨®å«åšç”²ç¡«æ°¨é…¸-è”—ç³–çš„è™•ç†æ–¹æ³•ï¼Œçœ‹çœ‹å®ƒå¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œå°¤å…¶æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶è€…å°4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†é€™ç¨®è™•ç†ï¼Œä¸¦åŒæ™‚è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç¶“éè”—ç³–è™•ç†çš„é’èŠ±æ¤°èœèŠ½ï¼Œå…¶è‘¡è„ç³–è‹·å«é‡ç«Ÿç„¶æé«˜äº†316.30%ï¼è€Œä¸”ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥å¾Œçš„é’èŠ±æ¤°èœèŠ½ç²‰ä¹Ÿä¿ç•™äº†é«˜æ¿ƒåº¦çš„è˜¿è””ç¡«ç´ ï¼Œå±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†å’Œæ²¹åˆ†ä¿æŒèƒ½åŠ›ã€‚æœ€ä»¤äººé©šè¨çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°æŸäº›ç´°èŒæœ‰é¡¯è‘—çš„æŠ—èŒæ•ˆæœï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥ä¿æŒé’èŠ±æ¤°èœèŠ½ç²‰çš„é«˜æ¿ƒåº¦è˜¿è””ç¡«ç´ ã€‚\n3. è˜¿è””ç¡«ç´ å°æŸäº›ç´°èŒå…·æŠ—èŒæ´»æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¥åº·ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main findings of a study on broccoli sprouts. Include simple illustrations of broccoli and sulforaphane, a simplified representation of the experiment subjects (like humans or cells), arrows or flow lines showing the experimental steps, and a section highlighting the main results such as increased nutrient levels and protective effects.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ‡‰ç”¨ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰æ­£é¢çš„å½±éŸ¿ï¼Œé€™å°æ–¼æ”¹å–„å‘¼å¸ç³»çµ±å¥åº·æˆ–é é˜²ç›¸é—œç–¾ç—…æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿äººå€‘åœ¨æ—¥å¸¸é£²é£Ÿä¸­å¢åŠ é€™äº›é£Ÿæçš„æ”å–ï¼Œä»¥ä¿ƒé€²å¥åº·å’Œå¢å¼·å…ç–«åŠ›ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ç‹€æ…‹ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å°æ–¼å‘¼å¸ç³»çµ±çš„å¥åº·è‡³é—œé‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ã€‚ç ”ç©¶è€…å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚GO-PEGå¥ˆç±³ç²’å­å‰‡æ˜¯å¾çŸ³å¢¨è£½æˆï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ï¼Œä»¥è©•ä¼°å…¶å°ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶é‚„ä½¿ç”¨äº†MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒå­˜æ´»ç‡å’Œæ¯’æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœå¼·èª¿äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œé›–ç„¶ä¸èƒ½ä¿è­‰å®ƒå€‘ä¸€å®šèƒ½æ²»ç™’æˆ–å®Œå…¨æœ‰æ•ˆï¼Œä½†å…¶æ½›åŠ›å€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ‡‰ç”¨ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰æ­£é¢çš„å½±éŸ¿ï¼Œé€™å°æ–¼æ”¹å–„å‘¼å¸ç³»çµ±å¥åº·æˆ–é é˜²ç›¸é—œç–¾ç—…æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿äººå€‘åœ¨æ—¥å¸¸é£²é£Ÿä¸­å¢åŠ é€™äº›é£Ÿæçš„æ”å–ï¼Œä»¥ä¿ƒé€²å¥åº·å’Œå¢å¼·å…ç–«åŠ›ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ç‹€æ…‹ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å°æ–¼å‘¼å¸ç³»çµ±çš„å¥åº·è‡³é—œé‡è¦ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ã€‚ç ”ç©¶è€…å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚GO-PEGå¥ˆç±³ç²’å­å‰‡æ˜¯å¾çŸ³å¢¨è£½æˆï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ï¼Œä»¥è©•ä¼°å…¶å°ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶é‚„ä½¿ç”¨äº†MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒå­˜æ´»ç‡å’Œæ¯’æ€§ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœå¼·èª¿äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œé›–ç„¶ä¸èƒ½ä¿è­‰å®ƒå€‘ä¸€å®šèƒ½æ²»ç™’æˆ–å®Œå…¨æœ‰æ•ˆï¼Œä½†å…¶æ½›åŠ›å€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å¤§å®¶çŸ¥é“å—ï¼Ÿæœ‰äº›é£Ÿæä¸åƒ…ç¾å‘³ï¼Œé‚„èƒ½å¹«åŠ©æˆ‘å€‘çš„å¥åº·ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°æˆ‘å€‘çš„å‘¼å¸ç³»çµ±æœ‰å¾ˆå¤§çš„å¥½è™•ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼äº†è§£ä¸€ç¨®å« PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©çš„å¥ˆç±³ç²’å­ï¼Œä»¥åŠè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“é€™äº›å¤©ç„¶æˆåˆ†å¦‚ä½•æ”¹å–„ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç™¼ç‚å’Œæ°§åŒ–å£“åŠ›æ–¹é¢çš„æ½›åŠ›ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦æ¸¬è©¦äº†å®ƒå°ç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½ä¸€ç¨®å« IL-6 çš„ç™¼ç‚æŒ‡æ¨™ï¼Œä¸¦æå‡æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œé€™å°æ–¼ä¿è­·æˆ‘å€‘çš„ç´°èƒéå¸¸é‡è¦ã€‚\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸ç³»çµ±æœ‰ç›Šã€‚\n2. å®ƒå€‘èƒ½é™ä½ç™¼ç‚æŒ‡æ¨™ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. å¤šåƒé€™äº›é£Ÿæå¯èƒ½æœ‰åŠ©æ–¼æå‡å…ç–«åŠ›ï¼Œè®“æˆ‘å€‘æ›´å¥åº·ï¼\n\nè¨˜å¾—åœ¨æ—¥å¸¸é£²é£Ÿä¸­åŠ å…¥é€™äº›å¥åº·é£Ÿæå“¦ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experiment and main results of a study on the effects of radish sulforaphane and black radish juice on human bronchial epithelial cells. Include simplified illustrations of radishes or broccoli to represent sulforaphane, a simplified depiction of human cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes such as reduced inflammation and increased antioxidant enzyme activity.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸ç³»çµ±ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰æ½›åœ¨å¥åº·ç›Šè™•çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå¯èƒ½å°äººé«”æœ‰æ­£é¢å½±éŸ¿ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è½‰æ›ç‡è¼ƒä½ï¼Œé€™æ„å‘³è‘—åœ¨å¯¦éš›æ‡‰ç”¨ä¸­ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°æé«˜å…¶ç”¢é‡æ˜¯éå¸¸é‡è¦çš„ã€‚é€éäº†è§£å¾®ç”Ÿç‰©å¦‚ä½•è½‰æ›é€™ç¨®åŒ–åˆç‰©ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´å¥½çš„æ–¹æ³•ä¾†åˆ©ç”¨é’èŠ±æ¤°èœä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„ç‡Ÿé¤Šè£œå……å“é–‹ç™¼æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æå‡å¤©ç„¶æˆåˆ†çš„ç”Ÿç‰©åˆ©ç”¨åº¦æ–¹é¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è…ºè‹·ï¼ˆglucoraphaninï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ æœ‰ç›Šå¥åº·ï¼Œä½†å…¶è½‰æ›éç¨‹ä¸­çš„æ•ˆç‡è¼ƒä½ï¼Œä¸”ç›®å‰å°æ–¼ä¹³é…¸èŒçš„è½‰æ›æ©Ÿåˆ¶å°šä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºé€™ä¸€è½‰æ›éç¨‹çš„ç´°ç¯€ï¼Œä¸¦å°‹æ‰¾æé«˜è½‰æ›ç‡çš„æ–¹æ³•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒå°è‘¡è„ç³–è…ºè‹·çš„è½‰æ›èƒ½åŠ›ã€‚ç ”ç©¶åœ˜éšŠè§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°ä¹³é…¸èŒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£é€™äº›è®ŠåŒ–å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä»£è¬è·¯å¾‘ã€‚é€™é …ç ”ç©¶çš„å°è±¡ä¸»è¦æ˜¯ä¹³é…¸èŒï¼Œä¸¦é€éæ”¹è®Šå…¶ç”Ÿé•·ç’°å¢ƒä¾†ä¿ƒé€²å…¶ä»£è¬èƒ½åŠ›çš„æå‡ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥æœ‰æ•ˆåœ°ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆéç¨‹ã€‚ç ”ç©¶é‚„æ­ç¤ºäº†è‘¡è„ç³–è…ºè‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰æ›è·¯å¾‘ï¼Œä¸¦æŒ‡å‡ºäº†ç›¸é—œçš„é…¶å’Œä»£è¬éç¨‹ã€‚é€™äº›çµæœç‚ºé€²ä¸€æ­¥äº†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰æ½›åœ¨å¥åº·ç›Šè™•çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå¯èƒ½å°äººé«”æœ‰æ­£é¢å½±éŸ¿ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è½‰æ›ç‡è¼ƒä½ï¼Œé€™æ„å‘³è‘—åœ¨å¯¦éš›æ‡‰ç”¨ä¸­ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°æé«˜å…¶ç”¢é‡æ˜¯éå¸¸é‡è¦çš„ã€‚é€éäº†è§£å¾®ç”Ÿç‰©å¦‚ä½•è½‰æ›é€™ç¨®åŒ–åˆç‰©ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´å¥½çš„æ–¹æ³•ä¾†åˆ©ç”¨é’èŠ±æ¤°èœä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„ç‡Ÿé¤Šè£œå……å“é–‹ç™¼æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æå‡å¤©ç„¶æˆåˆ†çš„ç”Ÿç‰©åˆ©ç”¨åº¦æ–¹é¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è…ºè‹·ï¼ˆglucoraphaninï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ æœ‰ç›Šå¥åº·ï¼Œä½†å…¶è½‰æ›éç¨‹ä¸­çš„æ•ˆç‡è¼ƒä½ï¼Œä¸”ç›®å‰å°æ–¼ä¹³é…¸èŒçš„è½‰æ›æ©Ÿåˆ¶å°šä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºé€™ä¸€è½‰æ›éç¨‹çš„ç´°ç¯€ï¼Œä¸¦å°‹æ‰¾æé«˜è½‰æ›ç‡çš„æ–¹æ³•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒå°è‘¡è„ç³–è…ºè‹·çš„è½‰æ›èƒ½åŠ›ã€‚ç ”ç©¶åœ˜éšŠè§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°ä¹³é…¸èŒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£é€™äº›è®ŠåŒ–å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä»£è¬è·¯å¾‘ã€‚é€™é …ç ”ç©¶çš„å°è±¡ä¸»è¦æ˜¯ä¹³é…¸èŒï¼Œä¸¦é€éæ”¹è®Šå…¶ç”Ÿé•·ç’°å¢ƒä¾†ä¿ƒé€²å…¶ä»£è¬èƒ½åŠ›çš„æå‡ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥æœ‰æ•ˆåœ°ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆéç¨‹ã€‚ç ”ç©¶é‚„æ­ç¤ºäº†è‘¡è„ç³–è…ºè‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰æ›è·¯å¾‘ï¼Œä¸¦æŒ‡å‡ºäº†ç›¸é—œçš„é…¶å’Œä»£è¬éç¨‹ã€‚é€™äº›çµæœç‚ºé€²ä¸€æ­¥äº†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„æˆåˆ†å—ï¼Ÿé€™å¯æ˜¯ä¸€å€‹æ½›åœ¨çš„å¥åº·å°è‹±é›„ï¼ä¸éï¼Œé›–ç„¶è˜¿è””ç¡«ç´ æœ‰å¾ˆå¤šå¥½è™•ï¼Œä½†æˆ‘å€‘èº«é«”è½‰æ›å®ƒçš„æ•ˆç‡ä¼¼ä¹ä¸å¤ªé«˜ï¼Œé€™è®“ç§‘å­¸å®¶å€‘é–‹å§‹æ¢ç´¢å¦‚ä½•æå‡é€™å€‹éç¨‹ã€‚  \n  \næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ï¼Œå°ˆæ³¨æ–¼å¦‚ä½•è®“ä¹³é…¸èŒï¼ˆä¹Ÿå°±æ˜¯æˆ‘å€‘å¸¸è½åˆ°çš„ç›Šç”ŸèŒï¼‰æ›´æœ‰æ•ˆåœ°æŠŠé’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è…ºè‹·ï¼Œè½‰æ›æˆè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸€äº›å¯¦é©—æŠ€è¡“ï¼Œè§€å¯Ÿä¸åŒçš„åŸ¹é¤Šæ¢ä»¶å°ä¹³é…¸èŒçš„å½±éŸ¿ï¼Œä¸¦åˆ†æäº†å®ƒå€‘çš„ä»£è¬è·¯å¾‘ã€‚  \n  \nçµæœç™¼ç¾ï¼Œç•¶æ”¹è®ŠåŸ¹é¤Šæ¢ä»¶æ™‚ï¼Œä¹³é…¸èŒçš„ä»£è¬è¡¨ç¾å‡ºä¸åŒçš„è®ŠåŒ–ï¼Œç‰¹åˆ¥æ˜¯ç¢³æ°´åŒ–åˆç‰©çš„ä»£è¬ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸çš„ä»£è¬å‰‡ä¸Šå‡ã€‚é€™æ„å‘³è‘—ï¼Œåªè¦èª¿æ•´ä¸€äº›å°ç´°ç¯€ï¼Œæˆ‘å€‘å°±æœ‰æ©Ÿæœƒä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆï¼  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ æœ‰æ½›åœ¨çš„å¥åº·ç›Šè™•ï¼Œä½†è½‰æ›æ•ˆç‡ä½ã€‚  \n2. ä¹³é…¸èŒèƒ½å¹«åŠ©è½‰æ›é’èŠ±æ¤°èœä¸­çš„æˆåˆ†ã€‚  \n3. èª¿æ•´åŸ¹é¤Šæ¢ä»¶èƒ½æé«˜è˜¿è””ç¡«ç´ çš„ç”Ÿæˆï¼  \n  \nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†æ›´å¤šçš„å¥åº·ç™¼ç¾å§ï¼",
    "image_prompt": "Create an informative flat design illustration on a light background. Include symbols representing broccoli and sulforaphane. Simplified illustrations of experimental subjects like cells or bacteria should be present. Use arrows or flow lines to indicate the experimental process. Include a section labeled 'Main Results' highlighting the increase in amino acid metabolism and the decrease in carbohydrate metabolism.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41412441",
    "title_en": "Sulforaphane Ameliorates DSS-Induced Colitis and Secondary Liver Injury in Mice: Proposed Mechanism in the SCFAs-FFAR2/3-Macrophage Polarization Axis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has shown therapeutic potential in inflammatory diseases. Our previous studies demonstrated that SFN ameliorates ulcerative colitis (UC) and restores gut microbiota composition in dextran sulfate sodium (DSS)-induced mice. In the present study, we further investigate the protective effects and underlying mechanisms of SFN against secondary liver injury associated with UC. The results revealed that SFN significantly alleviated pathological damage in both the colon and liver, improved liver function parameters, upregulated intestinal tight junction proteins and Muc2 expression, and inhibited inflammation in DSS-induced colitis mice. Additionally, SFN significantly elevated short-chain fatty acid (SCFA) concentrations, enhanced the expression of SCFA receptors (free fatty acid receptors 2 and 3, FFAR2/3), and modulated macrophage polarization by inhibiting M1 and promoting M2 phenotypes in the colon and liver. Collectively, these findings suggest that SFN may alleviate colitis and secondary liver injury by enhancing intestinal barrier function and reducing inflammatory responses, potentially via the SCFAs-FFAR2/3-macrophage polarization signaling cascade. Thus, SFN may serve as a promising adjunctive therapeutic agent for the prevention and treatment of UC.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ½›åœ¨çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç™¼ç‚æ€§ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚é€™é¡ç–¾ç—…ä¸­ï¼Œèƒ½å¤ æ”¹å–„è…¸é“å¥åº·å’Œè‚è‡ŸåŠŸèƒ½ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›ç–¾ç—…çš„é¢¨éšªï¼Œä¸¦æ”¹å–„ç›¸é—œçš„å¥åº·ç‹€æ³ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æ‰€å¼•èµ·çš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¸­ï¼Œé€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½æ¸›è¼•ç—…ç†æå‚·ä¸¦æ”¹å–„ç›¸é—œçš„ç”Ÿç†æŒ‡æ¨™ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œä¸¦çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶ä¸»è¦è§€å¯Ÿè˜¿è””ç¡«ç´ å°å°é¼ çš„è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç—…ç†æå‚·çš„æ”¹å–„ã€è‚åŠŸèƒ½æŒ‡æ¨™çš„è®ŠåŒ–ï¼Œä»¥åŠè…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’Œé»æ¶²è›‹ç™½çš„è¡¨é”æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦åŠå…¶å—é«”çš„è¡¨é”ï¼Œä¸¦åˆ†æäº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½æŒ‡æ¨™ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½åŠé»æ¶²è›‹ç™½çš„è¡¨é”ï¼ŒåŒæ™‚æŠ‘åˆ¶ç™¼ç‚åæ‡‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œä¿ƒé€²ç›¸é—œå—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶å¼•èµ·çš„è‚æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºè¼”åŠ©æ²»ç™‚åŠ‘çš„æ½›åŠ›ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ½›åœ¨çš„å•Ÿç¤ºã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç™¼ç‚æ€§ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚é€™é¡ç–¾ç—…ä¸­ï¼Œèƒ½å¤ æ”¹å–„è…¸é“å¥åº·å’Œè‚è‡ŸåŠŸèƒ½ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›ç–¾ç—…çš„é¢¨éšªï¼Œä¸¦æ”¹å–„ç›¸é—œçš„å¥åº·ç‹€æ³ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æ‰€å¼•èµ·çš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¸­ï¼Œé€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½æ¸›è¼•ç—…ç†æå‚·ä¸¦æ”¹å–„ç›¸é—œçš„ç”Ÿç†æŒ‡æ¨™ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œä¸¦çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶ä¸»è¦è§€å¯Ÿè˜¿è””ç¡«ç´ å°å°é¼ çš„è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç—…ç†æå‚·çš„æ”¹å–„ã€è‚åŠŸèƒ½æŒ‡æ¨™çš„è®ŠåŒ–ï¼Œä»¥åŠè…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’Œé»æ¶²è›‹ç™½çš„è¡¨é”æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦åŠå…¶å—é«”çš„è¡¨é”ï¼Œä¸¦åˆ†æäº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½æŒ‡æ¨™ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½åŠé»æ¶²è›‹ç™½çš„è¡¨é”ï¼ŒåŒæ™‚æŠ‘åˆ¶ç™¼ç‚åæ‡‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œä¿ƒé€²ç›¸é—œå—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶å¼•èµ·çš„è‚æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºè¼”åŠ©æ²»ç™‚åŠ‘çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ¿ ä½ çŸ¥é“è˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯æ˜¯å¾é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­æç…‰å‡ºä¾†çš„ç¥å¥‡æˆåˆ†ï¼æœ€è¿‘çš„ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰é€™ç¨®ç™¼ç‚æ€§ç–¾ç—…æœ‰å¾ˆå¥½çš„ä¿è­·ä½œç”¨ï¼Œç”šè‡³èƒ½æ”¹å–„è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ï¼Œç ”ç©¶äººå“¡ç”¨å°é¼ æ¨¡å‹ä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™ç¨®åŒ–åˆç‰©èƒ½æ¸›è¼•è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œä¸¦æ”¹å–„ä¸€äº›å¥åº·æŒ‡æ¨™ã€‚\n\nå…·é«”ä¾†èªªï¼Œç ”ç©¶è€…å€‘ç™¼ç¾è˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æå‡è…¸é“çš„ç·Šå¯†é€£æ¥è›‹ç™½å’Œé»æ¶²è›‹ç™½çš„è¡¨ç¾ï¼Œé‚„èƒ½æŠ‘åˆ¶ç™¼ç‚åæ‡‰ï¼Œå¢åŠ æœ‰ç›Šçš„çŸ­éˆè„‚è‚ªé…¸æ¿ƒåº¦ï¼Œé€™äº›éƒ½æ˜¯å°å¥åº·éå¸¸é‡è¦çš„ï¼\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“å’Œè‚è‡Ÿå¥åº·ã€‚\n2. å®ƒèƒ½æ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œæå‡è…¸é“å±éšœåŠŸèƒ½ã€‚\n3. æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœï¼Œæˆ–è¨±èƒ½é™ä½é€™äº›ç–¾ç—…çš„é¢¨éšªï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of the study on sulforaphane. Include simple icons representing broccoli or sulforaphane, a simplified depiction of experimental subjects (like mice), and arrows or flow lines indicating the experimental steps. Include a section labeled 'Main Results' that highlights protective effects and changes observed, using soft colors on a white or light background.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41412441/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±çš„åŒ–ç™‚é›–ç„¶æ˜¯ä¸»è¦çš„æ²»ç™‚æ‰‹æ®µï¼Œä½†å…¶æ•ˆæœæœ‰é™ä¸”å¯èƒ½ä¼´éš¨è‘—è¨±å¤šå‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°çš„å¤©ç„¶ç”¢å“æˆ–å…¶åˆæˆè¡ç”Ÿç‰©ï¼Œåƒæ˜¯é€™æ¬¡ç ”ç©¶ä¸­çš„è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„æ··åˆç‰©ï¼Œå¯èƒ½ç‚ºæ‚£è€…æä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœéƒ½æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ä¸‰é™°æ€§ä¹³ç™Œæ˜¯ä¸€ç¨®ç‰¹åˆ¥é›£ä»¥æ²»ç™‚çš„ä¹³ç™Œäºå‹ï¼Œä¸»è¦ä¾è³´åŒ–ç™‚ä¾†æ§åˆ¶ç—…æƒ…ã€‚ç ”ç©¶è€…å€‘é—œæ³¨æ–¼å¤©ç„¶ç”¢å“ï¼Œå°¤å…¶æ˜¯æœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ çš„åˆæˆæ··åˆç‰©ï¼Œå› ç‚ºé€™äº›æˆåˆ†åœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢é¡¯ç¤ºå‡ºè‰¯å¥½çš„æ½›åŠ›ã€‚é€éè¨­è¨ˆå’Œåˆæˆæ–°çš„åŒ–åˆç‰©ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æŠ—ç™Œè—¥ç‰©ï¼Œé€²ä¸€æ­¥æ”¹å–„ä¸‰é™°æ€§ä¹³ç™Œæ‚£è€…çš„æ²»ç™‚æ•ˆæœã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›åŒ–åˆç‰©åœ¨é«”å¤–çš„æ¸¬è©¦ä¸­ï¼Œç‰¹åˆ¥æ˜¯ç¬¬17è™ŸåŒ–åˆç‰©ï¼ˆ17aï¼‰ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—çš„æŠ—å¢æ®–æ´»æ€§ï¼Œä¸¦åœ¨ä¸åŒçš„ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¸­é€²è¡Œäº†æ¸¬è©¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä½¿ç”¨MDA-MB-231è…«ç˜¤æ¨¡å‹ä¾†è§€å¯Ÿ17açš„æ•ˆæœï¼Œä¸¦è©•ä¼°å…¶å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶ä½œç”¨åŠå…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¬¬17è™ŸåŒ–åˆç‰©ï¼ˆ17aï¼‰åœ¨æŠ—ç™Œæ–¹é¢å…·æœ‰å¾ˆé«˜çš„æ½›åŠ›ã€‚å®ƒä¸åƒ…åœ¨é«”å¤–æœ‰æ•ˆæŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²ï¼Œé‚„èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨é«”å…§å¯¦é©—ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶äº†è…«ç˜¤çš„ç”Ÿé•·ï¼Œä¸”æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ï¼Œé€™è¡¨æ˜å®ƒå°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿å¾ˆå°ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœç‚º17aä½œç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚å€™é¸è—¥ç‰©çš„æ½›åŠ›æä¾›äº†æ”¯æŒï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±çš„åŒ–ç™‚é›–ç„¶æ˜¯ä¸»è¦çš„æ²»ç™‚æ‰‹æ®µï¼Œä½†å…¶æ•ˆæœæœ‰é™ä¸”å¯èƒ½ä¼´éš¨è‘—è¨±å¤šå‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°çš„å¤©ç„¶ç”¢å“æˆ–å…¶åˆæˆè¡ç”Ÿç‰©ï¼Œåƒæ˜¯é€™æ¬¡ç ”ç©¶ä¸­çš„è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„æ··åˆç‰©ï¼Œå¯èƒ½ç‚ºæ‚£è€…æä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœéƒ½æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ä¸‰é™°æ€§ä¹³ç™Œæ˜¯ä¸€ç¨®ç‰¹åˆ¥é›£ä»¥æ²»ç™‚çš„ä¹³ç™Œäºå‹ï¼Œä¸»è¦ä¾è³´åŒ–ç™‚ä¾†æ§åˆ¶ç—…æƒ…ã€‚ç ”ç©¶è€…å€‘é—œæ³¨æ–¼å¤©ç„¶ç”¢å“ï¼Œå°¤å…¶æ˜¯æœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ çš„åˆæˆæ··åˆç‰©ï¼Œå› ç‚ºé€™äº›æˆåˆ†åœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢é¡¯ç¤ºå‡ºè‰¯å¥½çš„æ½›åŠ›ã€‚é€éè¨­è¨ˆå’Œåˆæˆæ–°çš„åŒ–åˆç‰©ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æŠ—ç™Œè—¥ç‰©ï¼Œé€²ä¸€æ­¥æ”¹å–„ä¸‰é™°æ€§ä¹³ç™Œæ‚£è€…çš„æ²»ç™‚æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›åŒ–åˆç‰©åœ¨é«”å¤–çš„æ¸¬è©¦ä¸­ï¼Œç‰¹åˆ¥æ˜¯ç¬¬17è™ŸåŒ–åˆç‰©ï¼ˆ17aï¼‰ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—çš„æŠ—å¢æ®–æ´»æ€§ï¼Œä¸¦åœ¨ä¸åŒçš„ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¸­é€²è¡Œäº†æ¸¬è©¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä½¿ç”¨MDA-MB-231è…«ç˜¤æ¨¡å‹ä¾†è§€å¯Ÿ17açš„æ•ˆæœï¼Œä¸¦è©•ä¼°å…¶å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶ä½œç”¨åŠå…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¬¬17è™ŸåŒ–åˆç‰©ï¼ˆ17aï¼‰åœ¨æŠ—ç™Œæ–¹é¢å…·æœ‰å¾ˆé«˜çš„æ½›åŠ›ã€‚å®ƒä¸åƒ…åœ¨é«”å¤–æœ‰æ•ˆæŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²ï¼Œé‚„èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨é«”å…§å¯¦é©—ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶äº†è…«ç˜¤çš„ç”Ÿé•·ï¼Œä¸”æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ï¼Œé€™è¡¨æ˜å®ƒå°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿å¾ˆå°ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœç‚º17aä½œç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚å€™é¸è—¥ç‰©çš„æ½›åŠ›æä¾›äº†æ”¯æŒï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶æœ‰å¯èƒ½å¹«åŠ©å°æŠ—ç™Œç—‡ï¼é€™æ¬¡çš„ç ”ç©¶èšç„¦åœ¨ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®éå¸¸é›£ä»¥æ²»ç™‚çš„ç™Œç—‡é¡å‹ï¼Œé€šå¸¸éœ€è¦åŒ–ç™‚ä¾†æ§åˆ¶ç—…æƒ…ã€‚ä¸éï¼Œç§‘å­¸å®¶å€‘æ­£åœ¨æ¢ç´¢æ–°çš„å¯èƒ½æ€§ï¼Œåƒæ˜¯å¤©ç„¶æˆåˆ†è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„æ··åˆç‰©ï¼Œå¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚\n\nç ”ç©¶åœ˜éšŠåˆæˆäº†15ç¨®æ–°åŒ–åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—ä¸­ç™¼ç¾ï¼Œç¬¬17è™ŸåŒ–åˆç‰©ï¼ˆ17aï¼‰åœ¨æŠ—ç™Œæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼å®ƒä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–ï¼Œé‚„èƒ½èª˜å°ç™Œç´°èƒè‡ªæˆ‘æ­»äº¡ï¼Œä¸¦åœ¨å‹•ç‰©å¯¦é©—ä¸­æˆåŠŸæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”å°æ­£å¸¸å™¨å®˜å½±éŸ¿ä¸å¤§ã€‚\n\né€™é …ç ”ç©¶çš„ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. å°ä¸‰é™°æ€§ä¹³ç™Œçš„ç ”ç©¶æ­£åœ¨å°‹æ‰¾æ–°çš„æ²»ç™‚é¸æ“‡ã€‚  \n2. ç¬¬17è™ŸåŒ–åˆç‰©é¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—ç™Œæ½›åŠ›ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†å¯èƒ½çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†åŸºç¤ï¼",
    "image_prompt": "Create a flat design infographic with a light background that visually explains the experimental process and key results of a study on a new anti-cancer compound. Include symbols for broccoli or compounds like sulforaphane, simplified illustrations of experimental subjects such as cells or animals, and arrows or flow lines indicating the steps of the experiment. Add a section highlighting the main results, such as protective effects or observed changes.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41399453",
    "title_en": "Dual effect of sulforaphane on multi-walled carbon nanotube-induced lung inflammation in mice.",
    "pub_date": "2025 Dec",
    "journal": "Toxicology research",
    "abstract_en": "A previous study demonstrated that Nrf2, a transcription factor, unexpectedly promoted multi-walled carbon nanotube (MWCNT)-induced lung inflammation in mice. This finding contrasts with the well-established role of Nrf2 in suppressing inflammatory responses induced by environmental chemicals, highlighting a critical knowledge gap. The present study investigated the effect of sulforaphane, a known activator of Nrf2, on MWCNT-induced lung inflammation in mice, in order to better understand the underlying mechanisms of this response. Each of 48 C57BL/6Â J male mouse was anesthetized and exposed once via pharyngeal aspiration to MWCNTs (Mitsui-7) at doses of 0, 10, or 20Â Î¼g in 40Â Î¼l of dispersion medium per mouse and treated thereafter with subcutaneous 25Â mg/kg/day sulforaphane or vehicle for 14Â days. Bronchoalveolar lavage fluid (BALF) was collected for differential cell counts. Lung tissues were processed for histopathological analysis and quantification of cytokine or chemokine mRNA expression and Nrf2 protein in nuclear extracts. MWCNTs exposure increased lung weight, BALF lymphocytes, and lung IL-6 expression. Sulforaphane attenuated MWCNTs-induced lung weight gain, lymphocytic infiltration, and upregulation of IL-6 expression, but paradoxically enhanced low-dose MWCNT-induced neutrophil infiltration in BALF, MIP-2 expression, and histopathological inflammation scores. These effects were accompanied by increased levels of active Nrf2 protein in nuclear extracts from lung tissue. Overall, the results indicate that sulforaphane suppresses lymphocyte infiltration while promoting neutrophil recruitment in response to low-dose MWCNTs, suggesting a dual effect of sulforaphane on MWCNT-induced lung inflammation mediated through Nrf2 activation.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚ºéƒ¨ç‚ç—‡çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ é€šå¸¸è¢«èªç‚ºæœ‰åŠ©æ–¼æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæœ‰æ‰€ä¸åŒã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨ç‰¹å®šçš„ç’°å¢ƒæˆ–åŠ‘é‡ä¸‹ï¼Œå¯èƒ½æœƒæœ‰æ„æƒ³ä¸åˆ°çš„çµæœã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥äº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼æœªä¾†çš„å¥åº·ç ”ç©¶å’Œç–¾ç—…é é˜²ç­–ç•¥æ˜¯éå¸¸é‡è¦çš„ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥åœ°äº†è§£Nrf2é€™å€‹è½‰éŒ„å› å­åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚ä»¥å¾€çš„ç ”ç©¶å·²ç¶“é¡¯ç¤ºï¼ŒNrf2åœ¨æŠ‘åˆ¶ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡åæ‡‰ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä½†é€™æ¬¡çš„ç ”ç©¶å»ç™¼ç¾å®ƒåœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½æœƒä¿ƒé€²ç‚ç—‡åæ‡‰ï¼Œé€™å¼•ç™¼äº†å°å…¶ä½œç”¨æ©Ÿåˆ¶çš„é€²ä¸€æ­¥æ¢è¨ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œé€šéå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰ï¼ŒåŠ‘é‡åˆ†åˆ¥ç‚º0ã€10æˆ–20å¾®å…‹ï¼Œä¸¦åœ¨æ¥ä¸‹ä¾†çš„14å¤©å…§ï¼Œçµ¦äºˆå°é¼ æ¯å¤©25æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§ç‰©è³ªã€‚ç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼ˆBALFï¼‰é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æä»¥åŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œæ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€BALFä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ å‰‡æ¸›å°‘äº†å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦é™ä½äº†IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººé©šè¨çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æš´éœ²ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œé€™é¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€éNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€è‚ºéƒ¨ç‚ç—‡åæ‡‰ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚ºéƒ¨ç‚ç—‡çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ é€šå¸¸è¢«èªç‚ºæœ‰åŠ©æ–¼æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæœ‰æ‰€ä¸åŒã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨ç‰¹å®šçš„ç’°å¢ƒæˆ–åŠ‘é‡ä¸‹ï¼Œå¯èƒ½æœƒæœ‰æ„æƒ³ä¸åˆ°çš„çµæœã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥äº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼æœªä¾†çš„å¥åº·ç ”ç©¶å’Œç–¾ç—…é é˜²ç­–ç•¥æ˜¯éå¸¸é‡è¦çš„ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥åœ°äº†è§£Nrf2é€™å€‹è½‰éŒ„å› å­åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚ä»¥å¾€çš„ç ”ç©¶å·²ç¶“é¡¯ç¤ºï¼ŒNrf2åœ¨æŠ‘åˆ¶ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡åæ‡‰ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä½†é€™æ¬¡çš„ç ”ç©¶å»ç™¼ç¾å®ƒåœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½æœƒä¿ƒé€²ç‚ç—‡åæ‡‰ï¼Œé€™å¼•ç™¼äº†å°å…¶ä½œç”¨æ©Ÿåˆ¶çš„é€²ä¸€æ­¥æ¢è¨ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œé€šéå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰ï¼ŒåŠ‘é‡åˆ†åˆ¥ç‚º0ã€10æˆ–20å¾®å…‹ï¼Œä¸¦åœ¨æ¥ä¸‹ä¾†çš„14å¤©å…§ï¼Œçµ¦äºˆå°é¼ æ¯å¤©25æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§ç‰©è³ªã€‚ç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼ˆBALFï¼‰é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æä»¥åŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œæ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€BALFä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ å‰‡æ¸›å°‘äº†å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦é™ä½äº†IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººé©šè¨çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æš´éœ²ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œé€™é¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€éNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€è‚ºéƒ¨ç‚ç—‡åæ‡‰ã€‚",
    "fb_post": "æ ¹æ“šã€ŠToxicology researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸ è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿé€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¸åƒ…è®“æˆ‘å€‘çš„èœè‰²æ›´ç¾å‘³ï¼Œé‚„å¯èƒ½å°å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å½±éŸ¿å“¦ï¼\n\næœ€è¿‘æœ‰ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¾Œçš„æƒ…æ³ã€‚ç ”ç©¶è€…ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œè®“å®ƒå€‘å¸å…¥ä¸åŒåŠ‘é‡çš„ç¢³ç´ç±³ç®¡ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„è‚ºéƒ¨åæ‡‰ï¼Œä¸¦çµ¦äºˆè˜¿è””ç¡«ç´ ä¾†çœ‹çœ‹æœƒç™¼ç”Ÿä»€éº¼è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç¢ºå¯¦èƒ½æ¸›å°‘å› ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨å•é¡Œï¼Œå¦‚è‚ºéƒ¨é‡é‡å¢åŠ å’Œç‚ç—‡æŒ‡æ¨™ä¸Šå‡ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å»æ˜¯ä¿ƒé€²äº†ç‚ç—‡åæ‡‰ï¼Œé€™è®“äººé©šè¨ï¼é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å½±éŸ¿ï¼Œå¯èƒ½æœƒå› ç’°å¢ƒæˆ–åŠ‘é‡ä¸åŒè€Œæœ‰æ‰€è®ŠåŒ–ã€‚\n\nğŸ” é€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›è‚ºéƒ¨ç‚ç—‡ã€‚\n2. ä½†åœ¨ç‰¹å®šæƒ…æ³ä¸‹ï¼Œå®ƒä¹Ÿå¯èƒ½ä¿ƒé€²ç‚ç—‡åæ‡‰ã€‚\n3. é€²ä¸€æ­¥äº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°å¥åº·ç ”ç©¶éå¸¸é‡è¦ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of the study on the effects of sulforaphane on lung inflammation caused by multi-walled carbon nanotubes (MWCNT). Include simple icons representing sulforaphane (like broccoli or radish), simplified representations of experimental subjects (like mice or cells), arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' showing protective effects and changes in inflammation levels.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºéƒ¨ç‚ç—‡ Lung Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41399453/"
  },
  {
    "id": "41409171",
    "title_en": "Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.",
    "pub_date": "2025 Dec",
    "journal": "ACS pharmacology & translational science",
    "abstract_en": "Sulforaphane (SFN) is a phytoderived compound abundant in cruciferous plants that possesses a broad spectrum of anticancer properties. We showed that SFN-induced caspase-mediated apoptosis in grade IV bone metastasis-derived androgen-insensitive PC-3 (IC<sub>50</sub> = 4.2 Î¼M), and lymph node metastasis-derived androgen-sensitive LNCaP (IC<sub>50</sub> = 2.8 Î¼M) prostate adenocarcinoma cells. SFN-mediated cardiotoxic side effects were tested in a preclinical in vitro model that enables the study simultaneously of the impact of drugs on cancer cell death and contractile properties of engineered heart tissues generated from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM EHT). Thereby, SFN exposure induced PC-3 cell death without affecting the contractile force of hiPSC-CM EHT. Interestingly, the irregular beating pattern of hiPSC-CM EHT observed in the presence of PC-3 coculture was normalized compared to vehicle treatment. Overall, this in vitro coculture model of hiPSC-CM EHT and cancer cells could facilitate the study of cardiotoxic cancer drug side-effects.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘æ¤ç‰©ä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®æŠ—ç™Œç‰¹æ€§ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡æ¤ç‰©çš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼Œæˆ–åœ¨æ²»ç™‚éç¨‹ä¸­ç™¼æ®è¼”åŠ©ä½œç”¨ã€‚é€™å°æ–¼å¸Œæœ›é€éè‡ªç„¶é£Ÿç‰©ä¾†æ”¹å–„å¥åº·çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸åŒé¡å‹çš„å‰åˆ—è…ºè…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ï¼Œä¸¦åŒæ™‚è©•ä¼°å…¶å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼ç™Œç—‡æ²»ç™‚ä¸­çš„å‰¯ä½œç”¨ç®¡ç†éå¸¸é‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒï¼ˆhiPSC-CMï¼‰ä¾†å»ºç«‹ä¸€å€‹é«”å¤–æ¨¡å‹ï¼Œé€™å€‹æ¨¡å‹èƒ½å¤ åŒæ™‚ç ”ç©¶ç™Œç´°èƒæ­»äº¡å’Œå¿ƒè‡Ÿçµ„ç¹”çš„æ”¶ç¸®ç‰¹æ€§ã€‚ç ”ç©¶è€…å°‡è˜¿è””ç¡«ç´ æ–½åŠ æ–¼ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼Œä¸¦è§€å¯Ÿå…¶å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¿ƒè‡Ÿç´°èƒçš„æ”¶ç¸®åŠ›æ˜¯å¦å—åˆ°å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä½†ä¸¦æœªå½±éŸ¿hiPSC-CMçš„æ”¶ç¸®åŠ›ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‡Ÿç´°èƒå…±åŒåŸ¹é¤Šæ™‚ï¼Œå¿ƒè‡Ÿç´°èƒçš„ç•°å¸¸è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸäº›æƒ…æ³ä¸‹å°å¿ƒè‡Ÿç´°èƒæœ‰ä¿è­·ä½œç”¨ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘æ¤ç‰©ä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®æŠ—ç™Œç‰¹æ€§ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡æ¤ç‰©çš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡çš„é¢¨éšªï¼Œæˆ–åœ¨æ²»ç™‚éç¨‹ä¸­ç™¼æ®è¼”åŠ©ä½œç”¨ã€‚é€™å°æ–¼å¸Œæœ›é€éè‡ªç„¶é£Ÿç‰©ä¾†æ”¹å–„å¥åº·çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸åŒé¡å‹çš„å‰åˆ—è…ºè…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ï¼Œä¸¦åŒæ™‚è©•ä¼°å…¶å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼ç™Œç—‡æ²»ç™‚ä¸­çš„å‰¯ä½œç”¨ç®¡ç†éå¸¸é‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒï¼ˆhiPSC-CMï¼‰ä¾†å»ºç«‹ä¸€å€‹é«”å¤–æ¨¡å‹ï¼Œé€™å€‹æ¨¡å‹èƒ½å¤ åŒæ™‚ç ”ç©¶ç™Œç´°èƒæ­»äº¡å’Œå¿ƒè‡Ÿçµ„ç¹”çš„æ”¶ç¸®ç‰¹æ€§ã€‚ç ”ç©¶è€…å°‡è˜¿è””ç¡«ç´ æ–½åŠ æ–¼ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼Œä¸¦è§€å¯Ÿå…¶å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¿ƒè‡Ÿç´°èƒçš„æ”¶ç¸®åŠ›æ˜¯å¦å—åˆ°å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä½†ä¸¦æœªå½±éŸ¿hiPSC-CMçš„æ”¶ç¸®åŠ›ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‡Ÿç´°èƒå…±åŒåŸ¹é¤Šæ™‚ï¼Œå¿ƒè‡Ÿç´°èƒçš„ç•°å¸¸è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸäº›æƒ…æ³ä¸‹å°å¿ƒè‡Ÿç´°èƒæœ‰ä¿è­·ä½œç”¨ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS pharmacology & translational scienceã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿé€™æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘æ¤ç‰©ä¸­æå–çš„ç¥å¥‡æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸Šæœ‰æ½›åœ¨çš„å¥½è™•ï¼é€™ç¯‡ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å°å…©ç¨®ä¸åŒå‹æ…‹çš„ç™Œç´°èƒï¼šä¸€ç¨®å°é›„æ¿€ç´ æ•æ„Ÿï¼Œå¦ä¸€ç¨®å‰‡ä¸æ•æ„Ÿã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ï¼Œä»¥åŠå®ƒå°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼ç™Œç—‡æ²»ç™‚éç¨‹ä¸­çš„å‰¯ä½œç”¨ç®¡ç†éå¸¸é‡è¦ã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†ä¸€ç¨®ä¾†è‡ªäººé¡å¹¹ç´°èƒçš„å¿ƒè‚Œç´°èƒä¾†å»ºç«‹æ¨¡å‹ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒå’Œå¿ƒè‡Ÿç´°èƒçš„è¡Œç‚ºã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°ä¸€ç¨®å‰åˆ—è…ºç™Œç´°èƒï¼ˆPC-3ï¼‰æ­»äº¡ï¼Œä½†å»ä¸å½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„æ”¶ç¸®åŠ›ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œç•¶é€™äº›ç™Œç´°èƒå’Œå¿ƒè‡Ÿç´°èƒä¸€èµ·åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‡Ÿç´°èƒçš„è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™å¯èƒ½æ„å‘³è‘—è˜¿è””ç¡«ç´ åœ¨æŸäº›æƒ…æ³ä¸‹å°å¿ƒè‡Ÿæœ‰ä¿è­·ä½œç”¨ï¼  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç™Œç—‡é¢¨éšªã€‚  \n2. å°å‰åˆ—è…ºç™Œç´°èƒæœ‰èª˜å°æ­»äº¡çš„æ•ˆæœã€‚  \n3. å¯èƒ½å°å¿ƒè‡Ÿç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of the study on sulforaphane. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of human or cell subjects, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‰åˆ—è…ºç™Œ Prostate Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41409171/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ–°è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯åœ¨å…ç–«è€å—æ€§æ–¹é¢ã€‚å…ç–«è€å—æ€§æœ‰åŠ©æ–¼é˜²æ­¢ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç™¼ç”Ÿï¼Œå› æ­¤æ”¹å–„å…ç–«ç³»çµ±çš„åŠŸèƒ½å¯èƒ½å°æ–¼é€™äº›ç–¾ç—…çš„é é˜²å’Œæ²»ç™‚éå¸¸é‡è¦ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ä¾†é”åˆ°é€™å€‹ç›®çš„ï¼Œé€™å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚çš„æœ‰æ•ˆç­–ç•¥ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ä¿ƒé€²å…ç–«ç³»çµ±çš„å¥åº·ï¼Œä¸¦ä¸”å¯èƒ½é–‹ç™¼å‡ºé‡å°ç‰¹å®šç–¾ç—…çš„ç²¾æº–ç™‚æ³•ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åŠå…¶è¡ç”Ÿç‰©åœ¨èª¿ç¯€äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒï¼ˆmoDCsï¼‰å…ç–«è€å—æ€§æ–¹é¢çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™äº›åŒ–åˆç‰©ä¾†ä¿ƒé€²æ¨¹çªç´°èƒçš„è€å—æ€§è¡¨å‹ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£NFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚é€™å°æ–¼é–‹ç™¼é‡å°ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æ²»ç™‚æ–¹æ³•å…·æœ‰é‡è¦æ„ç¾©ï¼Œå› ç‚ºæ¨¹çªç´°èƒåœ¨å…ç–«åæ‡‰ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç™¼ç‚ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ -å²©è—»ç³–ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›è™•ç†å°æ¨¹çªç´°èƒè¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€Tç´°èƒèª¿ç¯€èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„å½±éŸ¿ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒåŒ–åˆç‰©å°æ¨¹çªç´°èƒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦æ¢ç´¢å…¶æ½›åœ¨çš„æ²»ç™‚æ‡‰ç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿä¸Šå‡ã€‚æ­¤å¤–ï¼ŒSFNMané‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å¢äº†èª¿ç¯€æ€§Tç´°èƒï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚åŠŸèƒ½æ€§æ¸¬è©¦å’Œå…±èšç„¦é¡¯å¾®é¡è§€å¯Ÿçµæœé¡¯ç¤ºï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€ŒSFNFucå‰‡æ²’æœ‰é€™ç¨®æ•ˆæœã€‚é€™äº›çµæœç¢ºèªäº†NFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é—œéµè§’è‰²ï¼Œä¸¦ç‚ºæœªä¾†é‡å°ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–ç™‚æ³•æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ–°è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯åœ¨å…ç–«è€å—æ€§æ–¹é¢ã€‚å…ç–«è€å—æ€§æœ‰åŠ©æ–¼é˜²æ­¢ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç™¼ç”Ÿï¼Œå› æ­¤æ”¹å–„å…ç–«ç³»çµ±çš„åŠŸèƒ½å¯èƒ½å°æ–¼é€™äº›ç–¾ç—…çš„é é˜²å’Œæ²»ç™‚éå¸¸é‡è¦ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ä¾†é”åˆ°é€™å€‹ç›®çš„ï¼Œé€™å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚çš„æœ‰æ•ˆç­–ç•¥ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ä¿ƒé€²å…ç–«ç³»çµ±çš„å¥åº·ï¼Œä¸¦ä¸”å¯èƒ½é–‹ç™¼å‡ºé‡å°ç‰¹å®šç–¾ç—…çš„ç²¾æº–ç™‚æ³•ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åŠå…¶è¡ç”Ÿç‰©åœ¨èª¿ç¯€äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒï¼ˆmoDCsï¼‰å…ç–«è€å—æ€§æ–¹é¢çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™äº›åŒ–åˆç‰©ä¾†ä¿ƒé€²æ¨¹çªç´°èƒçš„è€å—æ€§è¡¨å‹ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£NFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚é€™å°æ–¼é–‹ç™¼é‡å°ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æ²»ç™‚æ–¹æ³•å…·æœ‰é‡è¦æ„ç¾©ï¼Œå› ç‚ºæ¨¹çªç´°èƒåœ¨å…ç–«åæ‡‰ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç™¼ç‚ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ -å²©è—»ç³–ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›è™•ç†å°æ¨¹çªç´°èƒè¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€Tç´°èƒèª¿ç¯€èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„å½±éŸ¿ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒåŒ–åˆç‰©å°æ¨¹çªç´°èƒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦æ¢ç´¢å…¶æ½›åœ¨çš„æ²»ç™‚æ‡‰ç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿä¸Šå‡ã€‚æ­¤å¤–ï¼ŒSFNMané‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å¢äº†èª¿ç¯€æ€§Tç´°èƒï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚åŠŸèƒ½æ€§æ¸¬è©¦å’Œå…±èšç„¦é¡¯å¾®é¡è§€å¯Ÿçµæœé¡¯ç¤ºï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€ŒSFNFucå‰‡æ²’æœ‰é€™ç¨®æ•ˆæœã€‚é€™äº›çµæœç¢ºèªäº†NFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é—œéµè§’è‰²ï¼Œä¸¦ç‚ºæœªä¾†é‡å°ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–ç™‚æ³•æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å…ç–«ç³»çµ±å…¶å¯¦å¯ä»¥é€éä¸€äº›å¤©ç„¶æˆåˆ†ä¾†è®Šå¾—æ›´å¼·å¤§ï¼æœ€è¿‘ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œé€™ä¸åƒ…æ˜¯å¥åº·é£²é£Ÿä¸­çš„ä¸€éƒ¨åˆ†ï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å…ç–«è€å—æ€§æœ‰å¾ˆå¤§çš„å¹«åŠ©ã€‚  \n  \né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„æ¨¹çªç´°èƒï¼ˆé€™æ˜¯ä¸€ç¨®å¹«åŠ©å…ç–«ç³»çµ±è­˜åˆ¥æ•µäººçš„ç´°èƒï¼‰ã€‚ç ”ç©¶è€…å€‘æŠŠé€™äº›ç´°èƒæ”¾åœ¨ç™¼ç‚çš„ç’°å¢ƒä¸­ï¼Œä¸¦ç”¨ä¸åŒçš„åŒ–åˆç‰©é€²è¡Œè™•ç†ï¼Œçœ‹çœ‹å®ƒå€‘çš„åæ‡‰ã€‚  \n  \nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ä¹‹ä¸€ï¼ŒSFNManï¼Œèƒ½å¤ æœ‰æ•ˆåœ°ä¿ƒé€²æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå€‘èƒ½æ›´å¥½åœ°æ§åˆ¶å…ç–«åæ‡‰ï¼Œæ¸›å°‘ä¸å¿…è¦çš„ç™¼ç‚åæ‡‰ã€‚è€Œä¸”ï¼ŒSFNMané‚„èƒ½ä¿ƒé€²ä¸€äº›æœ‰åŠ©æ–¼èª¿ç¯€å…ç–«çš„åˆ†å­ç”¢ç”Ÿï¼Œé€™å°æ–¼é é˜²è‡ªé«”å…ç–«ç–¾ç—…éå¸¸é‡è¦ï¼  \n  \nç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚  \n2. SFNManèƒ½é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§ï¼Œé™ä½ç™¼ç‚ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†é‡å°ç™¼ç‚åŠè‡ªé«”å…ç–«ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane (SFN) and its derivatives. The image should include simplified icons of broccoli or sulforaphane, human or cell representations as experimental subjects, and arrows or flow lines indicating the experimental steps. Include a section labeled 'Main Results' highlighting the protective effects observed, such as increased tolerance in dendritic cells and reduced inflammation. Use a light background with soft colors for a clear and educational presentation.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé«”å…ç–«ç–¾ç—… Autoimmune Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶å¡”å…‹èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å®ƒå¯¦éš›ä¸Šå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¤©ç„¶çš„Nrf2æ´»åŒ–åŠ‘ï¼Œå¯èƒ½åœ¨æ¸›è¼•TTSç›¸é—œçš„å¿ƒè‚Œæå‚·æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¡”å…‹èŒ²åšç—‡å€™ç¾¤ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®ç—‡å€™ç¾¤çš„ç—…ç†æ©Ÿåˆ¶ä¸­ï¼Œæ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰å¦‚ä½•å½±éŸ¿å¿ƒè‚Œçš„å¥åº·ï¼Œä»¥åŠæ˜¯å¦å¯ä»¥é€šéè˜¿è””ç¡«ç´ ä¾†æ”¹å–„é€™äº›æƒ…æ³ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½æ‰¾åˆ°é‡å°TTSçš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ï¼Œä»¥æ¸›å°‘å¿ƒè‚Œæå‚·ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚é€šéè§€å¯Ÿé€™äº›æ¨¡å‹çš„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œç ”ç©¶è€…è©•ä¼°äº†è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶ä¸­é‚„åˆ†æäº†æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡çš„æ¨™è¨˜ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç—…ç†éç¨‹ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„æ²»ç™‚èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·ï¼Œä¸¦æŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦å•Ÿå‹•Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚é¸æ“‡ï¼Œé‡å°TTSä¸­çš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡é€²è¡Œå¹²é ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶å¡”å…‹èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å®ƒå¯¦éš›ä¸Šå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¤©ç„¶çš„Nrf2æ´»åŒ–åŠ‘ï¼Œå¯èƒ½åœ¨æ¸›è¼•TTSç›¸é—œçš„å¿ƒè‚Œæå‚·æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¡”å…‹èŒ²åšç—‡å€™ç¾¤ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®ç—‡å€™ç¾¤çš„ç—…ç†æ©Ÿåˆ¶ä¸­ï¼Œæ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰å¦‚ä½•å½±éŸ¿å¿ƒè‚Œçš„å¥åº·ï¼Œä»¥åŠæ˜¯å¦å¯ä»¥é€šéè˜¿è””ç¡«ç´ ä¾†æ”¹å–„é€™äº›æƒ…æ³ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½æ‰¾åˆ°é‡å°TTSçš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ï¼Œä»¥æ¸›å°‘å¿ƒè‚Œæå‚·ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚é€šéè§€å¯Ÿé€™äº›æ¨¡å‹çš„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œç ”ç©¶è€…è©•ä¼°äº†è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶ä¸­é‚„åˆ†æäº†æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡çš„æ¨™è¨˜ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç—…ç†éç¨‹ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„æ²»ç™‚èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·ï¼Œä¸¦æŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦å•Ÿå‹•Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚é¸æ“‡ï¼Œé‡å°TTSä¸­çš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡é€²è¡Œå¹²é ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿå…¶å¯¦æœ‰äº›çœ‹ä¼¼ç„¡å®³çš„ç—‡ç‹€å¯èƒ½éš±è—è‘—å±æ©Ÿï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œå¡”å…‹èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ä¸åƒ…åƒ…æ˜¯å°æ¯›ç—…ï¼Œå®ƒå¯èƒ½æœƒå°è‡´å¿ƒè‡Ÿå—æï¼é€™è®“ç§‘å­¸å®¶å€‘é–‹å§‹å°‹æ‰¾èƒ½å¤ å¹«åŠ©æ”¹å–„é€™ç¨®æƒ…æ³çš„å¤©ç„¶æˆåˆ†ï¼Œçµæœä»–å€‘ç™¼ç¾äº†è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿TTSçš„å¿ƒè‡Ÿå¥åº·ã€‚ç ”ç©¶è€…å€‘åˆ©ç”¨å°é¼ å’Œå¿ƒè‡Ÿç´°èƒæ¨¡æ“¬TTSçš„æƒ…æ³ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚é€éæª¢æ¸¬æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æŒ‡æ¨™ï¼Œç ”ç©¶è€…å€‘å¸Œæœ›æ‰¾åˆ°æ¸›å°‘å¿ƒè‡Ÿæå‚·çš„æœ‰æ•ˆæ–¹æ³•ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæå‚·ï¼Œä¸¦æŠ‘åˆ¶ä¸è‰¯çš„ç´°èƒæ­»äº¡æ¨™è¨˜ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ï¼\n\nğŸ” é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚  \n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·ã€‚  \n3. é€™å¯èƒ½æˆç‚ºæ²»ç™‚TTSçš„æ–°é¸æ“‡ï¼",
    "image_prompt": "Create a flat design infographic explaining a study on the effects of sulforaphane in Takotsubo syndrome. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice and heart cells, and arrows or flow lines indicating the experimental steps. Add a section highlighting the main results, such as protective effects and changes observed in heart structure and function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å¡”å…‹èŒ²åšç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2025 Dec",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°é£²é£Ÿä¸­å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£Ÿç‰©ä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é¡¯è‘—é¢¨éšªã€‚ç ”ç©¶æŒ‡å‡ºï¼Œå¾åå­—èŠ±ç§‘è”¬èœä¸­æå–çš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·å¹²é æªæ–½å’Œæ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºå…©çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆè„«æ°§é›ªè…çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“å™¨å®˜é¡ä¼¼ç‰©ä¾†é€²ä¸€æ­¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡å’Œæµå¼ç´°èƒè¡“ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ”¹å–„äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ¢å¾©äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¸›å°‘äº†è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€šéå¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ä¾†ç™¼æ®ä¿è­·ä½œç”¨ï¼Œé€™ä¸€æ–°æ©Ÿåˆ¶ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°é£²é£Ÿä¸­å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£Ÿç‰©ä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é¡¯è‘—é¢¨éšªã€‚ç ”ç©¶æŒ‡å‡ºï¼Œå¾åå­—èŠ±ç§‘è”¬èœä¸­æå–çš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·å¹²é æªæ–½å’Œæ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºå…©çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆè„«æ°§é›ªè…çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“å™¨å®˜é¡ä¼¼ç‰©ä¾†é€²ä¸€æ­¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡å’Œæµå¼ç´°èƒè¡“ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ”¹å–„äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ¢å¾©äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¸›å°‘äº†è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€šéå¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ä¾†ç™¼æ®ä¿è­·ä½œç”¨ï¼Œé€™ä¸€æ–°æ©Ÿåˆ¶ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­å¯èƒ½éš±è—è‘—ä¸€ç¨®å«åšè„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰çš„éœ‰èŒæ¯’ç´ ï¼Œé€™å¯ä¸æ˜¯å¥½æ±è¥¿ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—é€™ç¨®æ¯’ç´ æ‰€é€ æˆçš„è…¸é“æå‚·ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•ä¿è­·è…¸é“ï¼Œä¸¦æ­ç¤ºå®ƒçš„é‹ä½œæ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†å°é¼ æ¨¡å‹ï¼Œå°‡å®ƒå€‘åˆ†æˆå…©çµ„ï¼Œä¸€çµ„çµ¦äºˆè„«æ°§é›ªè…çƒ¯é†‡ï¼Œå¦ä¸€çµ„å‰‡çµ¦äºˆè˜¿è””ç¡«ç´ ã€‚æ¥è‘—ï¼Œä»–å€‘è§€å¯Ÿäº†é€™äº›å°é¼ çš„è…¸é“è®ŠåŒ–ï¼Œä¸¦ç”¨ä¸€äº›ç§‘å­¸æŠ€è¡“ä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ¸›è¼•äº†è„«æ°§é›ªè…çƒ¯é†‡é€ æˆçš„è…¸é“æ¯’æ€§ï¼Œé‚„æ”¹å–„äº†è…¸é“çµæ§‹ï¼Œæ¢å¾©äº†ç´°èƒçš„å¥åº·ç‹€æ…‹ã€‚é€™äº›ç™¼ç¾ç‚ºæˆ‘å€‘æœªä¾†çš„å¥åº·é£²é£Ÿæä¾›äº†æ–°æ–¹å‘ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—é£Ÿç‰©ä¸­çš„éœ‰èŒæ¯’ç´ ã€‚\n2. ç ”ç©¶è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“å¥åº·ã€‚\n3. æ–°çš„ä¿è­·æ©Ÿåˆ¶ç‚ºæœªä¾†ç ”ç©¶æä¾›äº†å•Ÿç¤ºã€‚",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of a study on the protective effects of sulforaphane against deoxynivalenol (DON) toxicity. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå®³ã€‚é€™æ„å‘³è‘—é€éæ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œåƒæ˜¯é’èŠ±æ¤°èœï¼Œæˆ–è¨±èƒ½å¤ åœ¨ä¸€å®šç¨‹åº¦ä¸Šä¿è­·æˆ‘å€‘çš„è‚ºéƒ¨å¥åº·ï¼Œæ¸›å°‘å¸ç…™å¸¶ä¾†çš„è² é¢å½±éŸ¿ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„å£“åŠ›æŠµæŠ—èƒ½åŠ›ï¼Œä»¥åŠå®ƒåœ¨èª¿ç¯€SIRT1è¡¨é”ä¸­çš„è§’è‰²ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æ¸›è¼•å¸ç…™æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„æå®³ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œé€™äº›ç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é€éMTTæ¸¬è©¦è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè€åŒ–æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä»¥åŠæ°§åŒ–å£“åŠ›æŒ‡æ¨™å’Œç´°èƒå…§çš„éµå«é‡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œç ”ç©¶è€…å‰‡é€éè…¹è…”æ³¨å°„å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿè‚ºéƒ¨çš„çµ„ç¹”è®ŠåŒ–ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›è¼•å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„è‚ºéƒ¨çš„æ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿åŠNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€éå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å°æ–¼æ¸›è¼•å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå®³ã€‚é€™æ„å‘³è‘—é€éæ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œåƒæ˜¯é’èŠ±æ¤°èœï¼Œæˆ–è¨±èƒ½å¤ åœ¨ä¸€å®šç¨‹åº¦ä¸Šä¿è­·æˆ‘å€‘çš„è‚ºéƒ¨å¥åº·ï¼Œæ¸›å°‘å¸ç…™å¸¶ä¾†çš„è² é¢å½±éŸ¿ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„å£“åŠ›æŠµæŠ—èƒ½åŠ›ï¼Œä»¥åŠå®ƒåœ¨èª¿ç¯€SIRT1è¡¨é”ä¸­çš„è§’è‰²ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æ¸›è¼•å¸ç…™æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„æå®³ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œé€™äº›ç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é€éMTTæ¸¬è©¦è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè€åŒ–æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä»¥åŠæ°§åŒ–å£“åŠ›æŒ‡æ¨™å’Œç´°èƒå…§çš„éµå«é‡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œç ”ç©¶è€…å‰‡é€éè…¹è…”æ³¨å°„å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿè‚ºéƒ¨çš„çµ„ç¹”è®ŠåŒ–ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›è¼•å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„è‚ºéƒ¨çš„æ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿åŠNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€éå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å°æ–¼æ¸›è¼•å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ å¯èƒ½æ˜¯æˆ‘å€‘å°æŠ—å¸ç…™å‚·å®³çš„å°å¹«æ‰‹ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶é—œæ³¨å¸ç…™å°è‚ºéƒ¨çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€ æˆæ°§åŒ–å£“åŠ›ï¼Œè®“ç´°èƒå—æå’Œè€åŒ–ã€‚è€Œè˜¿è””ç¡«ç´ ï¼Œé€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„å¤©ç„¶æˆåˆ†ï¼Œä¼¼ä¹èƒ½å¹«åŠ©æ¸›è¼•é€™äº›æå®³ï¼ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œé€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½ä¿è­·æˆ‘å€‘çš„è‚ºéƒ¨ï¼Œæ¸›å°‘å¸ç…™çš„è² é¢å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘ç”¨äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ ä¾†æ¸¬è©¦è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œç•¶ç´°èƒæ¥è§¸åˆ°å¸ç…™æå–ç‰©æ™‚ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œç”šè‡³æ”¹å–„è‚ºéƒ¨çš„çµ„ç¹”è®ŠåŒ–ï¼\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚ºéƒ¨å¥åº·ï¼Œæ¸›å°‘å¸ç…™å¸¶ä¾†çš„æå®³ã€‚\n2. å®ƒèƒ½é€†è½‰å¸ç…™å¼•èµ·çš„ç´°èƒè€åŒ–å’Œæ°§åŒ–å£“åŠ›ã€‚\n3. æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ç›Šï¼\n\nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒè‚ºéƒ¨å¥åº·ï¼Œå¾é£²é£Ÿé–‹å§‹åšèµ·å§ï¼",
    "image_prompt": "Create a flat design infographic with a light background that illustrates the experiment and main results of a study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified icons of human cells and mice as experimental subjects, arrows or flow lines indicating the steps of the experiment, and a section labeled 'Main Results' highlighting protective effects and changes observed. Use soft colors for a friendly and educational look.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "çš®è†šè€åŒ–æ˜¯éš¨è‘—å¹´é½¡å¢é•·è€Œå‡ºç¾çš„ç¾è±¡ï¼Œæœƒå½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé€²è€Œå°è‡´èº«é«”çš„è„†å¼±æ„Ÿã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶çš„æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©çš®è†šå…§éƒ¨è€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚äº†è§£é€™äº›æ©Ÿåˆ¶ä¸åƒ…æœ‰åŠ©æ–¼æˆ‘å€‘æ›´å¥½åœ°èªè­˜çš®è†šè€åŒ–çš„éç¨‹ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„æŠ—è€åŒ–ç™‚æ³•æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©äººå€‘ç¶­æŒå¥åº·çš„çš®è†šç‹€æ…‹ï¼Œé€²è€Œæå‡ç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨çš®è†šå…§éƒ¨è€åŒ–ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ‰¾å‡ºå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é›–ç„¶è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å·²ç¶“æœ‰å»£æ³›çš„æ‡‰ç”¨ï¼Œä½†å…¶å°æ–¼çš®è†šè€åŒ–çš„å½±éŸ¿ä»ç„¶ä¸å¤ æ˜ç¢ºï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™æ–¹é¢çš„çŸ¥è­˜ç©ºç™½ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†æ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ã€‚ç ”ç©¶å°è±¡æ˜¯ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œç ”ç©¶è€…åœ¨å°é¼ çš„é£²é£Ÿä¸­æ·»åŠ äº†è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæœ‰åŠ©æ–¼æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹æ˜é¡¯æ”¹å–„ï¼Œæ°§åŒ–é‚„åŸå¹³è¡¡ä¹Ÿå¾—åˆ°äº†èª¿æ•´ï¼Œå…ç–«ç´°èƒçš„çµ„æˆä¹Ÿæœ‰äº†è®ŠåŒ–ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰çš®è†šè€åŒ–çš„è›‹ç™½è³ªè¡¨ç¾å‹ï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»é€™ä¸€ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "çš®è†šè€åŒ–æ˜¯éš¨è‘—å¹´é½¡å¢é•·è€Œå‡ºç¾çš„ç¾è±¡ï¼Œæœƒå½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé€²è€Œå°è‡´èº«é«”çš„è„†å¼±æ„Ÿã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶çš„æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©çš®è†šå…§éƒ¨è€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚äº†è§£é€™äº›æ©Ÿåˆ¶ä¸åƒ…æœ‰åŠ©æ–¼æˆ‘å€‘æ›´å¥½åœ°èªè­˜çš®è†šè€åŒ–çš„éç¨‹ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„æŠ—è€åŒ–ç™‚æ³•æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©äººå€‘ç¶­æŒå¥åº·çš„çš®è†šç‹€æ…‹ï¼Œé€²è€Œæå‡ç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨çš®è†šå…§éƒ¨è€åŒ–ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ‰¾å‡ºå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é›–ç„¶è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å·²ç¶“æœ‰å»£æ³›çš„æ‡‰ç”¨ï¼Œä½†å…¶å°æ–¼çš®è†šè€åŒ–çš„å½±éŸ¿ä»ç„¶ä¸å¤ æ˜ç¢ºï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™æ–¹é¢çš„çŸ¥è­˜ç©ºç™½ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†æ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ã€‚ç ”ç©¶å°è±¡æ˜¯ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œç ”ç©¶è€…åœ¨å°é¼ çš„é£²é£Ÿä¸­æ·»åŠ äº†è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæœ‰åŠ©æ–¼æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹æ˜é¡¯æ”¹å–„ï¼Œæ°§åŒ–é‚„åŸå¹³è¡¡ä¹Ÿå¾—åˆ°äº†èª¿æ•´ï¼Œå…ç–«ç´°èƒçš„çµ„æˆä¹Ÿæœ‰äº†è®ŠåŒ–ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰çš®è†šè€åŒ–çš„è›‹ç™½è³ªè¡¨ç¾å‹ï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»é€™ä¸€ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ æœ‰æ²’æœ‰æƒ³éï¼Œç‚ºä»€éº¼æˆ‘å€‘çš„çš®è†šæœƒéš¨è‘—å¹´é½¡å¢é•·è€Œè®Šå¾—è¶Šä¾†è¶Šè„†å¼±å‘¢ï¼Ÿé€™ä¸åƒ…å½±éŸ¿å¤–è²Œï¼Œé‚„å¯èƒ½å½±éŸ¿æ•´é«”çš„å¥åº·æ„Ÿã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œæƒ³è¦äº†è§£å®ƒå¦‚ä½•å¹«åŠ©æˆ‘å€‘çš„çš®è†šæŠµæŠ—è€åŒ–ï¼\n\né€™é …ç ”ç©¶çš„ç›®æ¨™æ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨çš®è†šå…§éƒ¨è€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç‰¹åˆ¥çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ 18å€‹æœˆå¤§ï¼Œä»£è¡¨è‘—è‡ªç„¶è€åŒ–çš„ç‹€æ…‹ã€‚ä»–å€‘åœ¨å°é¼ çš„é£²é£Ÿä¸­åŠ å…¥äº†è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿçš®è†šçš„çµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡ï¼ˆé€™æ˜¯ç¶­æŒç´°èƒå¥åº·çš„é‡è¦æŒ‡æ¨™ï¼‰å’Œå…ç–«ç´°èƒçš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è£œå……ï¼Œé€™äº›å°é¼ çš„çš®è†šçµæ§‹æœ‰äº†æ˜é¡¯æ”¹å–„ï¼Œæ°§åŒ–é‚„åŸå¹³è¡¡ä¹Ÿè®Šå¾—æ›´å¥½ï¼Œå…ç–«ç´°èƒçš„çµ„æˆä¹Ÿæœ‰äº†è®ŠåŒ–ï¼æœ‰è¶£çš„æ˜¯ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é€†è½‰çš®è†šè€åŒ–çš„æŸäº›è›‹ç™½è³ªè¡¨ç¾ï¼Œä¸¦ä¸”æ¿€æ´»äº†ä¸€æ¢åç‚ºapelinçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™å¯èƒ½æ˜¯æ”¹å–„çš®è†šå¥åº·çš„é—œéµã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„çš®è†šçµæ§‹å’ŒåŠŸèƒ½ã€‚\n2. å®ƒå¯èƒ½é€éèª¿æ•´æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒä¾†å°æŠ—çš®è†šè€åŒ–ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æŠ—è€åŒ–ç™‚æ³•æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on the effects of sulforaphane on skin aging. The design should be flat and simple, with a white or light-colored background and soft color palette. Include symbols for broccoli or sulforaphane, simplified representations of experimental subjects like mice, arrows or flow lines to indicate the steps of the experiment, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "çš®è†šè€åŒ– Skin Aging",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç¶­è­·å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€²ä¸€æ­¥ä¿ƒé€²æ•´é«”å¥åº·ï¼Œé€™å°æ–¼å¸Œæœ›å¢å¼·å…ç–«ç³»çµ±å’Œç¶­æŒè‚è‡ŸåŠŸèƒ½çš„äººä¾†èªªï¼Œéƒ½æ˜¯å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«èª˜å°çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿åŠè…¸é“å¾®ç”Ÿç‰©çµ„å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®åŒ–å­¸ç‰©è³ªå°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™äº›éç¨‹ä¸­çš„æ½›åœ¨ä¿è­·æ©Ÿåˆ¶ï¼Œé€²è€Œç‚ºç›¸é—œçš„å¥åº·å•é¡Œæä¾›è§£æ±ºæ–¹æ¡ˆã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œä¸¦å°å…¶é€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„è®ŠåŒ–ï¼Œä¸¦åˆ†æè…¸é“å¾®ç”Ÿç‰©çµ„çš„è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²æœƒé¡¯è‘—å¼•èµ·è‚è‡Ÿæ¯’æ€§ï¼Œé€™è¡¨ç¾åœ¨è‚è‡Ÿç¸½è†½é¹¼é…¸å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä»¥åŠæŸäº›åŸºå› è¡¨é”çš„è®ŠåŒ–ä¸Šã€‚è€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡èƒ½æ¸›å°‘è†½é¹¼é…¸çš„ç©ç´¯ï¼Œä¸¦æ¢å¾©åŸºå› è¡¨é”çš„æ­£å¸¸æ°´å¹³ï¼Œå¾è€Œæ¸›è¼•ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆï¼Œå¢åŠ æœ‰ç›ŠèŒç¾¤ï¼Œä¸¦æ¢å¾©è…¸é“çš„è½‰éŒ„çµ„å¤±èª¿ï¼Œé€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ¯’æ€§ç·©è§£ç­–ç•¥ä¸­çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç¶­è­·å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€²ä¸€æ­¥ä¿ƒé€²æ•´é«”å¥åº·ï¼Œé€™å°æ–¼å¸Œæœ›å¢å¼·å…ç–«ç³»çµ±å’Œç¶­æŒè‚è‡ŸåŠŸèƒ½çš„äººä¾†èªªï¼Œéƒ½æ˜¯å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«èª˜å°çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿åŠè…¸é“å¾®ç”Ÿç‰©çµ„å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®åŒ–å­¸ç‰©è³ªå°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™äº›éç¨‹ä¸­çš„æ½›åœ¨ä¿è­·æ©Ÿåˆ¶ï¼Œé€²è€Œç‚ºç›¸é—œçš„å¥åº·å•é¡Œæä¾›è§£æ±ºæ–¹æ¡ˆã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œä¸¦å°å…¶é€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„è®ŠåŒ–ï¼Œä¸¦åˆ†æè…¸é“å¾®ç”Ÿç‰©çµ„çš„è®ŠåŒ–ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²æœƒé¡¯è‘—å¼•èµ·è‚è‡Ÿæ¯’æ€§ï¼Œé€™è¡¨ç¾åœ¨è‚è‡Ÿç¸½è†½é¹¼é…¸å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä»¥åŠæŸäº›åŸºå› è¡¨é”çš„è®ŠåŒ–ä¸Šã€‚è€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡èƒ½æ¸›å°‘è†½é¹¼é…¸çš„ç©ç´¯ï¼Œä¸¦æ¢å¾©åŸºå› è¡¨é”çš„æ­£å¸¸æ°´å¹³ï¼Œå¾è€Œæ¸›è¼•ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆï¼Œå¢åŠ æœ‰ç›ŠèŒç¾¤ï¼Œä¸¦æ¢å¾©è…¸é“çš„è½‰éŒ„çµ„å¤±èª¿ï¼Œé€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ¯’æ€§ç·©è§£ç­–ç•¥ä¸­çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ å¤§å®¶çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„è‚è‡Ÿå’Œå…ç–«ç³»çµ±æœ‰ä¿è­·ä½œç”¨ï¼é€™æ˜¯ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆå°±æ˜¯è˜¿è””è£¡çš„å¤©ç„¶æˆåˆ†ï¼‰å¦‚ä½•å¹«åŠ©å°æŠ—ä¸‰è‹¯éŒ«é€™ç¨®åŒ–å­¸ç‰©è³ªå°é­šé¡çš„å½±éŸ¿ã€‚\n\nç ”ç©¶è€…å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚ä¸€çµ„æ˜¯å°ç…§çµ„ï¼Œå¦ä¸€çµ„å‰‡æ˜¯æ¥å—ä¸‰è‹¯éŒ«çš„é­šï¼Œæœ€å¾Œä¸€çµ„å‰‡æ˜¯åŒæ™‚æ¥å—ä¸‰è‹¯éŒ«å’Œè˜¿è””ç¡«ç´ ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œä»–å€‘è§€å¯Ÿåˆ°äº†ä¸åŒè™•ç†å°é­šçš„å¥åº·å½±éŸ¿ã€‚\n\nçµæœç™¼ç¾ï¼Œä¸‰è‹¯éŒ«æœƒå°é­šçš„è‚è‡Ÿé€ æˆå‚·å®³ï¼Œè®“æŸäº›æŒ‡æ¨™ä¸Šå‡ï¼Œå½±éŸ¿å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚ä½†æ˜¯ï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½æ¸›å°‘é€™äº›å‚·å®³ï¼Œå¹«åŠ©æ¢å¾©æ­£å¸¸çš„ç”Ÿç†ç‹€æ…‹ï¼Œç”šè‡³æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼\n\nğŸ’¡ é€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚è‡Ÿå’Œå…ç–«ç³»çµ±ã€‚\n2. ä¸‰è‹¯éŒ«å°å¥åº·æœ‰å®³ï¼Œä½†è˜¿è””ç¡«ç´ èƒ½æ¸›è¼•é€™ç¨®å½±éŸ¿ã€‚\n3. æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„å°å¥åº·ä¹Ÿæœ‰æ­£é¢å½±éŸ¿ï¼\n\nè®“æˆ‘å€‘ä¸€èµ·é—œæ³¨é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ï¼Œç‚ºå¥åº·åŠ åˆ†ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on the protective effects of sulforaphane from radishes against the toxicity of tributyltin in fish. The design should be flat and simple, with a white or light-colored background and soft color palette. Include icons representing sulforaphane (like broccoli or radishes) and simplified illustrations of fish. Use arrows or flow lines to show the experimental steps. Include a section labeled 'Main Results' highlighting the protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿å¯èƒ½èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œè€Œé€™åˆèˆ‡æ½°ç˜æ€§çµè…¸ç‚çš„ç™¼å±•å¯†åˆ‡ç›¸é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚æœ‰ç›Šï¼Œé€™æ„å‘³è‘—é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œæ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œæˆ–è¨±èƒ½å¤ å¹«åŠ©é é˜²æˆ–ç·©è§£é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•å’Œæ”¹å–„è…¸é“å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç”±ç¡«é…¸å³æ—‹ç³–è‹·èª˜å°çš„çµè…¸ç‚å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œä¸¦ä¸”å®ƒçš„ä½œç”¨æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ åœ¨è…¸é“å¥åº·ä¸­çš„æ½›åœ¨è§’è‰²ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç¡«é…¸å³æ—‹ç³–è‹·èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚ä»–å€‘çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬åˆ†æè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆè®ŠåŒ–ï¼Œä»¥åŠé€²è¡Œæœªé‡å°æ€§çš„ä»£è¬çµ„å­¸åˆ†æï¼Œä»¥è©•ä¼°è…¸é“å…§çš„ä»£è¬ç‰©è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨å…¨é¢äº†è§£è˜¿è””ç¡«ç´ å°è…¸é“å¥åº·çš„å½±éŸ¿åŠå…¶æ½›åœ¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†çµè…¸ç‚å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”ä»£è¬çµ„å­¸åˆ†ææŒ‡å‡ºï¼Œèˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬ç‰©çš„æ°´å¹³ç™¼ç”Ÿäº†é¡¯è‘—è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚èƒ½å¤ æŠ‘åˆ¶èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘çµè…¸ç‚çš„ç‚ç—‡ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿å¯èƒ½èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œè€Œé€™åˆèˆ‡æ½°ç˜æ€§çµè…¸ç‚çš„ç™¼å±•å¯†åˆ‡ç›¸é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚æœ‰ç›Šï¼Œé€™æ„å‘³è‘—é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œæ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œæˆ–è¨±èƒ½å¤ å¹«åŠ©é é˜²æˆ–ç·©è§£é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•å’Œæ”¹å–„è…¸é“å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç”±ç¡«é…¸å³æ—‹ç³–è‹·èª˜å°çš„çµè…¸ç‚å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œä¸¦ä¸”å®ƒçš„ä½œç”¨æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ åœ¨è…¸é“å¥åº·ä¸­çš„æ½›åœ¨è§’è‰²ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ä¾æ“šã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç¡«é…¸å³æ—‹ç³–è‹·èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚ä»–å€‘çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬åˆ†æè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆè®ŠåŒ–ï¼Œä»¥åŠé€²è¡Œæœªé‡å°æ€§çš„ä»£è¬çµ„å­¸åˆ†æï¼Œä»¥è©•ä¼°è…¸é“å…§çš„ä»£è¬ç‰©è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨å…¨é¢äº†è§£è˜¿è””ç¡«ç´ å°è…¸é“å¥åº·çš„å½±éŸ¿åŠå…¶æ½›åœ¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†çµè…¸ç‚å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”ä»£è¬çµ„å­¸åˆ†ææŒ‡å‡ºï¼Œèˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬ç‰©çš„æ°´å¹³ç™¼ç”Ÿäº†é¡¯è‘—è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚èƒ½å¤ æŠ‘åˆ¶èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘çµè…¸ç‚çš„ç‚ç—‡ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„è˜¿è””ç¡«ç´ å¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„ç–¾ç—…ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹ç ”ç©¶è€…ç™¼ç¾äº†ä»€éº¼ï¼\n\nç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç”±ç‰¹å®šç‰©è³ªå¼•èµ·çš„çµè…¸ç‚å°é¼ çš„æƒ…æ³ã€‚ä»–å€‘çµ¦é€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿè…¸é“çš„è®ŠåŒ–ã€‚ä»–å€‘åˆ†æäº†è…¸é“è£¡çš„å¾®ç”Ÿç‰©çµ„æˆï¼Œä»¥åŠè…¸é“å…§çš„å„ç¨®ä»£è¬ç‰©è®ŠåŒ–ã€‚é€™æ¨£çš„ç ”ç©¶è¨­è¨ˆï¼Œè®“ä»–å€‘èƒ½æ›´å…¨é¢åœ°äº†è§£è˜¿è””ç¡«ç´ å°è…¸é“å¥åº·çš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çµè…¸ç‚å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©è…¸é“çš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘ç‚ç—‡ï¼æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿå› ç‚ºè˜¿è””ç¡«ç´ è€Œé‡æ–°å¹³è¡¡ï¼Œé€™å°è…¸é“å¥åº·æ˜¯å€‹å¥½æ¶ˆæ¯ï¼\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚\n2. ç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ã€‚\n3. å®ƒé‚„èƒ½èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¿ƒé€²è…¸é“å¥åº·ï¼",
    "image_prompt": "Create a simple and informative illustration that explains the experimental methods and main results of a study on the effects of sulforaphane from radishes on colitis. The illustration should have a flat design style with a white or light-colored background and soft colors. Include symbolic representations of radishes or sulforaphane, simplified illustrations of experimental subjects such as mice, and arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½åœ¨æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·å’Œæ¸›å°‘ç‚ç—‡åæ‡‰æ–¹é¢è¡¨ç¾å‡ºæ›´å¥½çš„æ•ˆæœã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æé«˜è—¥ç‰©ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦æ–¹é¢ï¼Œè®“æ²»ç™‚æ›´æœ‰æ•ˆã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°å°é¼ åŸƒçˆ¾åˆ©å¸Œè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç™Œç—‡æ¨¡å‹ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œå°é¼ çš„ç”Ÿå­˜ç‡ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦æ¢ç´¢å…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACçš„å°é¼ çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç­‰æŒ‡æ¨™ï¼Œä»¥è©•ä¼°ä¸åŒè™•ç†çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼è‡ªç”±å½¢å¼çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³é…æ–¹é‚„èƒ½æ”¹å–„å°é¼ çš„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘DNAæ–·è£‚å’Œæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«æ€§ç‚ç—‡åæ‡‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œç´°èƒå‡‹äº¡ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½åœ¨æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·å’Œæ¸›å°‘ç‚ç—‡åæ‡‰æ–¹é¢è¡¨ç¾å‡ºæ›´å¥½çš„æ•ˆæœã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æé«˜è—¥ç‰©ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦æ–¹é¢ï¼Œè®“æ²»ç™‚æ›´æœ‰æ•ˆã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°å°é¼ åŸƒçˆ¾åˆ©å¸Œè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç™Œç—‡æ¨¡å‹ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œå°é¼ çš„ç”Ÿå­˜ç‡ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦æ¢ç´¢å…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACçš„å°é¼ çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç­‰æŒ‡æ¨™ï¼Œä»¥è©•ä¼°ä¸åŒè™•ç†çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼è‡ªç”±å½¢å¼çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³é…æ–¹é‚„èƒ½æ”¹å–„å°é¼ çš„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘DNAæ–·è£‚å’Œæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«æ€§ç‚ç—‡åæ‡‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œç´°èƒå‡‹äº¡ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰å€‹ç¥å¥‡æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿæœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€™ç¨®æˆåˆ†ä¸åƒ…å°å¥åº·æœ‰å¥½è™•ï¼Œé‚„å¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸­ç™¼æ®é‡è¦ä½œç”¨ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°å°é¼ åŸƒçˆ¾åˆ©å¸Œè…¹æ°´ç™Œï¼ˆEACï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œå°é¼ çš„ç”Ÿå­˜ç‡ã€‚ä»–å€‘ç”¨90éš»é›Œæ€§ç‘å£«ç™½é¼ é€²è¡Œå¯¦é©—ï¼Œå°‡ç‰ å€‘åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œè§€å¯Ÿä¸åŒè™•ç†ä¸‹çš„è…«ç˜¤é«”ç©å’Œå­˜æ´»ç‡ç­‰æŒ‡æ¨™ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç¶“éç´ç±³è„‚è³ªé«”åŒ…è£¹å¾Œï¼Œå°è…«ç˜¤çš„æŠ‘åˆ¶æ•ˆæœæ¯”è‡ªç”±å½¢å¼çš„è˜¿è””ç¡«ç´ æ›´é¡¯è‘—ï¼é€™ä¸åƒ…æœ‰åŠ©æ–¼æ¸›å°‘è…«ç˜¤é«”ç©ï¼Œé‚„èƒ½æ”¹å–„å°é¼ çš„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›ï¼Œèª¿ç¯€å…¨èº«æ€§ç‚ç—‡åæ‡‰ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚\n2. ç¶“éç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ æ•ˆæœæ›´ä½³ã€‚\n3. é€™ç¨®æˆåˆ†é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on sulforaphane. Include symbols representing broccoli and sulforaphane, simplified illustrations of mice as experimental subjects, and arrows or flow lines indicating the steps of the experiment. Include a section labeled 'Main Results' highlighting protective effects and changes observed, using soft colors on a white or light background.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "åŸƒçˆ¾åˆ©å¸Œè…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚èƒƒç™Œçš„ç­–ç•¥ï¼Œå¹«åŠ©æ‚£è€…æ”¹å–„ç”Ÿå­˜ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æ–¼ç›¸é—œé•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰CKMT2-AS1çš„èª¿æ§ä½œç”¨ã€‚é€™äº›ç ”ç©¶çµæœå¯èƒ½æ­ç¤ºå‡ºæ–°çš„æ²»ç™‚é¶é»ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£èƒƒç™Œçš„ç™¼å±•ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„lncRNAã€‚æ¥è‘—ï¼Œé€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šSTAT3-CKMT2-AS1èª¿æ§è»¸ä¸­æ¶‰åŠçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ã€‚é€™äº›å¯¦é©—çš„å°è±¡åŒ…æ‹¬äººé¡èƒƒç™Œç´°èƒå’Œç›¸é—œçš„å‹•ç‰©æ¨¡å‹ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸‹èª¿lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€Œå…¶éè¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§è¡¨ç¾ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„èƒƒç™Œæ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚èƒƒç™Œçš„ç­–ç•¥ï¼Œå¹«åŠ©æ‚£è€…æ”¹å–„ç”Ÿå­˜ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æ–¼ç›¸é—œé•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰CKMT2-AS1çš„èª¿æ§ä½œç”¨ã€‚é€™äº›ç ”ç©¶çµæœå¯èƒ½æ­ç¤ºå‡ºæ–°çš„æ²»ç™‚é¶é»ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£èƒƒç™Œçš„ç™¼å±•ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„lncRNAã€‚æ¥è‘—ï¼Œé€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šSTAT3-CKMT2-AS1èª¿æ§è»¸ä¸­æ¶‰åŠçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ã€‚é€™äº›å¯¦é©—çš„å°è±¡åŒ…æ‹¬äººé¡èƒƒç™Œç´°èƒå’Œç›¸é—œçš„å‹•ç‰©æ¨¡å‹ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸‹èª¿lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€Œå…¶éè¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§è¡¨ç¾ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„èƒƒç™Œæ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ï¼Œç«Ÿç„¶éš±è—è‘—æŠ—ç™Œçš„æ½›åŠ›ï¼é€™æ¬¡çš„ç ”ç©¶èšç„¦æ–¼è˜¿è””ç¡«ç´ ï¼Œé€™æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­çš„åŒ–åˆç‰©ï¼Œå¯èƒ½å°èƒƒç™Œçš„æ²»ç™‚å¸¶ä¾†æ–°çš„å¸Œæœ›ã€‚ ç ”ç©¶äººå“¡æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå°ä¸€ç¨®å«åšCKMT2-AS1çš„é•·éˆéç·¨ç¢¼RNAçš„å½±éŸ¿ã€‚é€™äº›RNAåœ¨ç™Œç´°èƒä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚çš„ç›®æ¨™ã€‚ é€éå¯¦é©—ï¼Œç ”ç©¶åœ˜éšŠä½¿ç”¨äº†äººé¡èƒƒç™Œç´°èƒå’Œå‹•ç‰©æ¨¡å‹ï¼Œé€²è¡Œäº†æ·±å…¥çš„åˆ†æã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½CKMT2-AS1çš„è¡¨é”ï¼Œé€™èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚ç•¶CKMT2-AS1çš„è¡¨é”è¢«æŠ‘åˆ¶æ™‚ï¼Œç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»éƒ½é¡¯è‘—æ¸›å°‘ã€‚é€™äº›çµæœç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼ ä¾†çœ‹çœ‹é€™äº›é‡é»ï¼š 1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶èƒƒç™Œç´°èƒçš„å¢é•·ã€‚ 2. CKMT2-AS1åœ¨èƒƒç™Œä¸­çš„é«˜è¡¨é”èˆ‡ç”Ÿå­˜ç‡ä½ç›¸é—œã€‚ 3. æŠ‘åˆ¶CKMT2-AS1å¯èƒ½æ˜¯æœªä¾†æ²»ç™‚çš„é—œéµï¼",
    "image_prompt": "Create a flat design infographic on a light background that visually explains the research on the anti-cancer effects of sulforaphane from cruciferous vegetables like broccoli. Include simplified illustrations of human and animal models, cancer cells, and arrows or flow lines to represent the experimental process. Highlight a section for 'Main Results' showcasing the protective effects of sulforaphane and the relationship between CKMT2-AS1 expression and cancer cell behavior.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶çš„æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„é£²é£Ÿè£œå……æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰æ½›åŠ›ï¼Œä½†ç›®å‰å°å…¶ç™‚æ•ˆçš„çœ‹æ³•ä»ç„¶å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶å…·é«”çš„è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å’Œæ•ˆæœï¼Œå°æ–¼è‡ªé–‰ç—‡çš„é é˜²å’Œæ²»ç™‚å¯èƒ½å…·æœ‰é‡è¦çš„å•Ÿç¤ºã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆåŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œåˆ†æç¾æœ‰çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„è£œå……å°è‡ªé–‰ç—‡ç—‡ç‹€çš„å½±éŸ¿ï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¯èƒ½çš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…èƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ä¾æ“šã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨Review Manager 5.4é€²è¡Œäº†çµ±åˆåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚é€™é …ç ”ç©¶å…±ç´å…¥äº†å…­å€‹è©¦é©—ï¼Œæ¶‰åŠ333ååƒèˆ‡è€…ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ç­‰æ–¹æ³•ï¼Œä¾†æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦è©•ä¼°å…¶å°ç¤¾äº¤åæ‡‰é‡è¡¨çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œå‡é¡¯è‘—é™ä½äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯çš„æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°ä¸è‰¯äº‹ä»¶çš„é¡¯è‘—å·®ç•°ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°é€šè·¯ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€šéæŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ï¼Œä»¥åŠèª¿ç¯€è‡ªå™¬ä¾†ç™¼æ®å…¶æ•ˆæœã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†æ”¯æŒã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶çš„æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„é£²é£Ÿè£œå……æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰æ½›åŠ›ï¼Œä½†ç›®å‰å°å…¶ç™‚æ•ˆçš„çœ‹æ³•ä»ç„¶å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶å…·é«”çš„è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å’Œæ•ˆæœï¼Œå°æ–¼è‡ªé–‰ç—‡çš„é é˜²å’Œæ²»ç™‚å¯èƒ½å…·æœ‰é‡è¦çš„å•Ÿç¤ºã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆåŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œåˆ†æç¾æœ‰çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„è£œå……å°è‡ªé–‰ç—‡ç—‡ç‹€çš„å½±éŸ¿ï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¯èƒ½çš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…èƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ä¾æ“šã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨Review Manager 5.4é€²è¡Œäº†çµ±åˆåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚é€™é …ç ”ç©¶å…±ç´å…¥äº†å…­å€‹è©¦é©—ï¼Œæ¶‰åŠ333ååƒèˆ‡è€…ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ç­‰æ–¹æ³•ï¼Œä¾†æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦è©•ä¼°å…¶å°ç¤¾äº¤åæ‡‰é‡è¡¨çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œå‡é¡¯è‘—é™ä½äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯çš„æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°ä¸è‰¯äº‹ä»¶çš„é¡¯è‘—å·®ç•°ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°é€šè·¯ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€šéæŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ï¼Œä»¥åŠèª¿ç¯€è‡ªå™¬ä¾†ç™¼æ®å…¶æ•ˆæœã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™å€‹å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œæœ€è¿‘åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„ç ”ç©¶ä¸­å¼•èµ·äº†ä¸å°‘é—œæ³¨ï¼ğŸŒ±\n\nç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¹«åŠ©æ”¹å–„è‡ªé–‰ç—‡çš„ç—‡ç‹€ã€‚ä»–å€‘é€²è¡Œäº†ä¸€é …ç³»çµ±æ€§çš„å›é¡§ï¼Œåˆ†æäº†å¤šå€‹éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œé€™äº›è©¦é©—ä¸­ç¸½å…±åŒ…æ‹¬äº†333ä½åƒèˆ‡è€…ï¼Œä¸¦ä½¿ç”¨äº†å¤šç¨®ç§‘å­¸æ–¹æ³•ä¾†æ¢ç´¢è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œç„¡è«–æ˜¯è£œå……4-5é€±é‚„æ˜¯8-10é€±ï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†éƒ½æœ‰é¡¯è‘—æ”¹å–„ï¼Œé€™æ„å‘³è‘—ä»–å€‘åœ¨ç¤¾äº¤äº’å‹•ä¸Šå¯èƒ½è®Šå¾—æ›´å¥½ï¼è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æ²’æœ‰ç™¼ç¾æ˜é¡¯çš„ä¸è‰¯åæ‡‰ï¼Œé€™è®“äººæ„Ÿåˆ°æ”¾å¿ƒã€‚\n\né€™é …ç ”ç©¶é‚„æ­ç¤ºäº†è˜¿è””ç¡«ç´ å¯èƒ½é€šéæŠ—æ°§åŒ–ã€æŠ—ç‚å’Œèª¿ç¯€ç´°èƒè‡ªå™¬ç­‰æ–¹å¼ç™¼æ®ä½œç”¨ã€‚é›–ç„¶é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªï¼Œä½†é€™äº›ç™¼ç¾ç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†æ”¯æŒã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰å¹«åŠ©ã€‚\n2. ç ”ç©¶é¡¯ç¤ºè£œå……å¾Œç¤¾äº¤åæ‡‰æœ‰é¡¯è‘—æ”¹å–„ã€‚\n3. æ²’æœ‰è§€å¯Ÿåˆ°é¡¯è‘—çš„ä¸è‰¯åæ‡‰ï¼Œå®‰å…¨æ€§è‰¯å¥½ã€‚",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane, a natural antioxidant. The image should have a simple, flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans or cells), arrows or flow lines indicating the steps of the experiment, and a section labeled 'Main Results' highlighting the protective effects observed. Use clear and concise visuals to convey the information effectively.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨å¥½è™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œèª¿ç¯€å…ç–«çš„ç‰¹æ€§ã€‚é€™äº›ç‰¹æ€§å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤å¾Œçš„å¥åº·ç‹€æ³ï¼Œæ¸›å°‘æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œå¾è€Œæé«˜ç§»æ¤æˆåŠŸçš„æ©Ÿæœƒã€‚é€™å°æ–¼æœªä¾†çš„å™¨å®˜ç§»æ¤ç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å°‹æ‰¾æ›´æœ‰æ•ˆçš„å…ç–«æŠ‘åˆ¶ç­–ç•¥æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œä¸¦æ¢è¨å…¶åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤å™¨å®˜å­˜æ´»ä¸­çš„ä½œç”¨ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºç›®å‰å°æ–¼å¦‚ä½•æœ‰æ•ˆé é˜²æ€¥æ€§æ’æ–¥åæ‡‰çš„äº†è§£ä»ç„¶æœ‰é™ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿åˆ°è¨±å¤šæ¥å—å™¨å®˜ç§»æ¤çš„ç—…äººçš„ç”Ÿæ´»å“è³ªå’Œå¥åº·ç‹€æ³ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å°é¼ çš„çš®è†šç§»æ¤æ¨¡å‹ã€‚é€™äº›å°é¼ åˆ†ç‚ºä¾›é«”å’Œæ¥å—è€…ï¼Œä¾›é«”å°é¼ çš„çš®è†šè¢«ç§»æ¤åˆ°æ¥å—è€…å°é¼ èº«ä¸Šã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚å¯¦é©—çµæœé¡¯ç¤ºï¼Œç¶“éæ²»ç™‚çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„å™¨å®˜å­˜æ´»ç‡æ˜é¡¯æé«˜ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨ç§»æ¤éç¨‹ä¸­ç™¼æ®äº†é‡è¦çš„ä½œç”¨ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„å™¨å®˜å­˜æ´»ç‡é”åˆ°80%ï¼Œè€Œæœªç¶“è™•ç†çš„å°é¼ å‰‡åœ¨ç¬¬9å¤©æ™‚100%å‡ºç¾å™¨å®˜æå¤±ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ çš®è†šä¸­ç™¼ç‚ç´°èƒçš„æ•¸é‡è¼ƒå°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘äº†å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©äº†æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­æœ‰æ½›åŠ›æˆç‚ºä¸€å€‹æœ‰å‰æ™¯çš„ç ”ç©¶å°è±¡ï¼Œæœªä¾†å¯ä»¥èˆ‡ç¾æœ‰çš„å…ç–«æŠ‘åˆ¶æ–¹æ¡ˆçµåˆé€²è¡Œé€²ä¸€æ­¥çš„ç ”ç©¶ã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨å¥½è™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œèª¿ç¯€å…ç–«çš„ç‰¹æ€§ã€‚é€™äº›ç‰¹æ€§å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤å¾Œçš„å¥åº·ç‹€æ³ï¼Œæ¸›å°‘æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œå¾è€Œæé«˜ç§»æ¤æˆåŠŸçš„æ©Ÿæœƒã€‚é€™å°æ–¼æœªä¾†çš„å™¨å®˜ç§»æ¤ç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å°‹æ‰¾æ›´æœ‰æ•ˆçš„å…ç–«æŠ‘åˆ¶ç­–ç•¥æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œä¸¦æ¢è¨å…¶åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤å™¨å®˜å­˜æ´»ä¸­çš„ä½œç”¨ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºç›®å‰å°æ–¼å¦‚ä½•æœ‰æ•ˆé é˜²æ€¥æ€§æ’æ–¥åæ‡‰çš„äº†è§£ä»ç„¶æœ‰é™ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿åˆ°è¨±å¤šæ¥å—å™¨å®˜ç§»æ¤çš„ç—…äººçš„ç”Ÿæ´»å“è³ªå’Œå¥åº·ç‹€æ³ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å°é¼ çš„çš®è†šç§»æ¤æ¨¡å‹ã€‚é€™äº›å°é¼ åˆ†ç‚ºä¾›é«”å’Œæ¥å—è€…ï¼Œä¾›é«”å°é¼ çš„çš®è†šè¢«ç§»æ¤åˆ°æ¥å—è€…å°é¼ èº«ä¸Šã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚å¯¦é©—çµæœé¡¯ç¤ºï¼Œç¶“éæ²»ç™‚çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„å™¨å®˜å­˜æ´»ç‡æ˜é¡¯æé«˜ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨ç§»æ¤éç¨‹ä¸­ç™¼æ®äº†é‡è¦çš„ä½œç”¨ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼Œç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„å™¨å®˜å­˜æ´»ç‡é”åˆ°80%ï¼Œè€Œæœªç¶“è™•ç†çš„å°é¼ å‰‡åœ¨ç¬¬9å¤©æ™‚100%å‡ºç¾å™¨å®˜æå¤±ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ çš®è†šä¸­ç™¼ç‚ç´°èƒçš„æ•¸é‡è¼ƒå°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘äº†å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©äº†æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­æœ‰æ½›åŠ›æˆç‚ºä¸€å€‹æœ‰å‰æ™¯çš„ç ”ç©¶å°è±¡ï¼Œæœªä¾†å¯ä»¥èˆ‡ç¾æœ‰çš„å…ç–«æŠ‘åˆ¶æ–¹æ¡ˆçµåˆé€²è¡Œé€²ä¸€æ­¥çš„ç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œå¤§å®¶å¥½ï¼ä»Šå¤©æƒ³è·Ÿä½ å€‘èŠèŠä¸€å€‹æœ‰è¶£çš„ç ”ç©¶ï¼Œé—œæ–¼æˆ‘å€‘çš„å¥åº·å’Œå™¨å®˜ç§»æ¤ï¼ä½ çŸ¥é“å—ï¼Ÿæ€¥æ€§æ’æ–¥åæ‡‰åœ¨å™¨å®˜ç§»æ¤ä¸­æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œå¯èƒ½æœƒå½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚ä¸éï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå¯èƒ½æœƒæœ‰åŠ©æ–¼æ”¹å–„é€™å€‹æƒ…æ³ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å°æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œä¸¦åœ¨å°é¼ çš„çš®è†šç§»æ¤æ¨¡å‹ä¸­é€²è¡Œå¯¦é©—ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨äº†ä¸€ç¨®å«æœ‰è˜¿è””ç¡«ç´ çš„æ°´å‡è† ï¼Œçœ‹çœ‹å®ƒå¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä¸¦è§€å¯Ÿç§»æ¤å™¨å®˜çš„å­˜æ´»æƒ…æ³ã€‚çµæœé¡¯ç¤ºï¼Œç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ ï¼Œå™¨å®˜å­˜æ´»ç‡é«˜é”80%ï¼è€Œæœªç¶“è™•ç†çš„å°é¼ å‰‡åœ¨ç¬¬9å¤©æ™‚å…¨éƒ¨å‡ºç¾å™¨å®˜æå¤±ã€‚\n\né€™äº›çµæœè®“äººæŒ¯å¥®ï¼Œå› ç‚ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œæœªä¾†æˆ–è¨±èƒ½æˆç‚ºå™¨å®˜ç§»æ¤çš„æ½›åœ¨æ–°åŠ©åŠ›ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n- è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚\n- æ¸›å°‘å…ç–«ç´°èƒæ´»åŒ–ï¼Œå»¶ç·©æ’æ–¥åæ‡‰ã€‚\n- æœªä¾†å¯èƒ½èˆ‡ç¾æœ‰å…ç–«æŠ‘åˆ¶æ–¹æ¡ˆçµåˆé€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified figures of mice as experimental subjects, and arrows or flow lines to show the experimental steps. Include a section labeled 'Main Results' highlighting the protective effects observed, such as increased organ survival rates.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ã€‚éš¨è‘—äººå€‘å°å¥åº·é£²é£Ÿçš„é‡è¦–ï¼Œäº†è§£é€™é¡å¤©ç„¶åŒ–åˆç‰©çš„æ½›åœ¨ç›Šè™•ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æˆ‘å€‘åœ¨æ—¥å¸¸ç”Ÿæ´»ä¸­åšå‡ºæ›´å¥åº·çš„é¸æ“‡ï¼Œä¸¦ä¿ƒé€²ç–¾ç—…çš„é é˜²ã€‚ç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é€™æ¨£çš„é‡å¤§ç–¾ç—…ä¸Šï¼Œæ¢ç´¢å¤©ç„¶æˆåˆ†çš„æ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para2": "é€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®åŒ–åˆç‰©å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ–¼ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©å­¸é€”å¾‘çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›å•é¡Œçš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡çš„ç™¼å±•æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæ–°çš„æ²»ç™‚æ–¹æ³•æä¾›ä¾æ“šã€‚",
    "para3": "é€™é …ç ”ç©¶ä¸»è¦æ˜¯é€šéæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œçš„ï¼Œç ”ç©¶è€…åˆ†æäº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚é€™äº›åˆ†æå¹«åŠ©ç ”ç©¶è€…äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥æå‡å…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©å­¸é€”å¾‘ä¸Šå…·æœ‰æ½›åœ¨çš„å½±éŸ¿ï¼Œé€™äº›é€”å¾‘åŒ…æ‹¬ä¿ƒé€²ç´°èƒå‡‹äº¡å’ŒæŠ‘åˆ¶ç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºç™Œç—‡æ²»ç™‚çš„ä¸€å€‹æœ‰å¸Œæœ›çš„è¼”åŠ©é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨çµåˆå…¶ä»–æ²»ç™‚æ–¹æ³•æ™‚ï¼Œå¯èƒ½æœƒå±•ç¾å‡ºæ›´å¥½çš„æ•ˆæœã€‚ç„¶è€Œï¼Œé€™äº›ç™¼ç¾ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„è‡¨åºŠæ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ã€‚éš¨è‘—äººå€‘å°å¥åº·é£²é£Ÿçš„é‡è¦–ï¼Œäº†è§£é€™é¡å¤©ç„¶åŒ–åˆç‰©çš„æ½›åœ¨ç›Šè™•ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æˆ‘å€‘åœ¨æ—¥å¸¸ç”Ÿæ´»ä¸­åšå‡ºæ›´å¥åº·çš„é¸æ“‡ï¼Œä¸¦ä¿ƒé€²ç–¾ç—…çš„é é˜²ã€‚ç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é€™æ¨£çš„é‡å¤§ç–¾ç—…ä¸Šï¼Œæ¢ç´¢å¤©ç„¶æˆåˆ†çš„æ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\né€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®åŒ–åˆç‰©å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ–¼ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©å­¸é€”å¾‘çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›å•é¡Œçš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡çš„ç™¼å±•æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæ–°çš„æ²»ç™‚æ–¹æ³•æä¾›ä¾æ“šã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é€šéæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œçš„ï¼Œç ”ç©¶è€…åˆ†æäº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚é€™äº›åˆ†æå¹«åŠ©ç ”ç©¶è€…äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥æå‡å…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©å­¸é€”å¾‘ä¸Šå…·æœ‰æ½›åœ¨çš„å½±éŸ¿ï¼Œé€™äº›é€”å¾‘åŒ…æ‹¬ä¿ƒé€²ç´°èƒå‡‹äº¡å’ŒæŠ‘åˆ¶ç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºç™Œç—‡æ²»ç™‚çš„ä¸€å€‹æœ‰å¸Œæœ›çš„è¼”åŠ©é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨çµåˆå…¶ä»–æ²»ç™‚æ–¹æ³•æ™‚ï¼Œå¯èƒ½æœƒå±•ç¾å‡ºæ›´å¥½çš„æ•ˆæœã€‚ç„¶è€Œï¼Œé€™äº›ç™¼ç¾ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„è‡¨åºŠæ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç¥å¥‡æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶è®“æˆ‘å€‘æ›´äº†è§£å®ƒåœ¨æŠ—ç™Œæ–¹é¢çš„æ½›åŠ›ï¼é€™ç¯‡ç ”ç©¶ä¸»è¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„æ˜¯ï¼Œå®ƒå¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„ä¸åŒä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿åƒè¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ï¼ˆä¹Ÿå°±æ˜¯ç´°èƒè‡ªæˆ‘æ­»äº¡ï¼‰ã€ç´°èƒé€±æœŸå’Œç‚ç—‡ç­‰éç¨‹ã€‚\n\né€™é …ç ”ç©¶æ˜¯é€šéåˆ†æéå»çš„æ–‡ç»ä¾†é€²è¡Œçš„ï¼Œç ”ç©¶è€…æª¢è¦–äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œåƒæ˜¯ç‚ç—‡ä»‹è³ªå’Œä¸€äº›ç‰¹å®šçš„è›‹ç™½è³ªï¼Œé€™æœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£è˜¿è””ç¡«ç´ åœ¨ç´°èƒå±¤é¢ä¸Šçš„ä½œç”¨ã€‚ä»–å€‘é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å¦‚ä½•èˆ‡è˜¿è””ç¡«ç´ å”åŒä½œç”¨ï¼Œå¯èƒ½å¢å¼·å…¶åœ¨æ²»ç™‚ä¸­çš„æ•ˆæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ä¿ƒé€²ç™Œç´°èƒå‡‹äº¡å’ŒæŠ‘åˆ¶ç‚ç—‡åæ‡‰ä¸Šæœ‰æ½›åœ¨å½±éŸ¿ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æˆç‚ºç™Œç—‡æ²»ç™‚çš„è¼”åŠ©é¸æ“‡ï¼Œå°¤å…¶æ˜¯èˆ‡å…¶ä»–ç™‚æ³•çµåˆæ™‚ï¼Œæ•ˆæœå¯èƒ½æ›´ä½³ã€‚ä¸éï¼Œé€™äº›ç™¼ç¾ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…·é«”çš„è‡¨åºŠæ‡‰ç”¨åƒ¹å€¼ã€‚\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå°æŠ—ç™Œæœ‰æ½›åŠ›ã€‚\n2. ç ”ç©¶æ¢è¨äº†å®ƒå¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©éç¨‹ã€‚\n3. é€²ä¸€æ­¥çš„ç ”ç©¶å°‡ç¢ºèªå®ƒçš„è‡¨åºŠæ‡‰ç”¨åƒ¹å€¼ã€‚",
    "image_prompt": "Create an infographic that explains the experimental approach and main findings of a study on sulforaphane, a compound from broccoli. The design should be flat-style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like human cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œå·²è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æå°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é›–ç„¶ç ”ç©¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ çš„æ•ˆæœæœ‰é™ï¼Œä½†å®ƒä»ç„¶æä¾›äº†é€²ä¸€æ­¥æ¢ç´¢çš„åŸºç¤ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„æŸäº›ç—‡ç‹€æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç²¾ç¥åˆ†è£‚ç—‡çš„æ­£å‘å’Œè² å‘ç—‡ç‹€ã€‚é€éç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œç ”ç©¶è€…å€‘æª¢è¦–äº†å¤šé …éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTï¼‰ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦åˆ†æå…¶å°æ‚£è€…çš„å½±éŸ¿ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦ç´å…¥äº†369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„å››é …éš¨æ©Ÿå°ç…§è©¦é©—ã€‚é€™äº›è©¦é©—ä¸»è¦è©•ä¼°è˜¿è””ç¡«ç´ å°æ‚£è€…çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ä½¿ç”¨æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰ä¾†æ¸¬é‡ç—‡ç‹€è®ŠåŒ–ï¼Œä»¥åŠå…¶ä»–èªçŸ¥æŒ‡æ¨™å’Œä»£è¬æ¨™è¨˜ã€‚ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„æ‚£è€…çš„æ•´é«”ç²¾ç¥ç—…ç†å­¸ç‹€æ³ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚æ•´é«”ç²¾ç¥ç—…ç†å­¸çš„å¾—åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œç„¶è€Œåœ¨æœ€æ–°çš„éš¨è¨ªä¸­ï¼Œé€™äº›æ”¹å–„ä¸¦æœªæŒçºŒã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æ¨™è¨˜ï¼ˆå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼‰æœ‰é¡¯è‘—çš„é™ä½æ•ˆæœï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚å„˜ç®¡é€™äº›çµæœæä¾›äº†åˆæ­¥çš„è¦‹è§£ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™å’Œç•°è³ªæ€§ï¼Œç ”ç©¶çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œå·²è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æå°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é›–ç„¶ç ”ç©¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ çš„æ•ˆæœæœ‰é™ï¼Œä½†å®ƒä»ç„¶æä¾›äº†é€²ä¸€æ­¥æ¢ç´¢çš„åŸºç¤ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„æŸäº›ç—‡ç‹€æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç²¾ç¥åˆ†è£‚ç—‡çš„æ­£å‘å’Œè² å‘ç—‡ç‹€ã€‚é€éç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œç ”ç©¶è€…å€‘æª¢è¦–äº†å¤šé …éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTï¼‰ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦åˆ†æå…¶å°æ‚£è€…çš„å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦ç´å…¥äº†369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„å››é …éš¨æ©Ÿå°ç…§è©¦é©—ã€‚é€™äº›è©¦é©—ä¸»è¦è©•ä¼°è˜¿è””ç¡«ç´ å°æ‚£è€…çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ä½¿ç”¨æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰ä¾†æ¸¬é‡ç—‡ç‹€è®ŠåŒ–ï¼Œä»¥åŠå…¶ä»–èªçŸ¥æŒ‡æ¨™å’Œä»£è¬æ¨™è¨˜ã€‚ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„æ‚£è€…çš„æ•´é«”ç²¾ç¥ç—…ç†å­¸ç‹€æ³ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚æ•´é«”ç²¾ç¥ç—…ç†å­¸çš„å¾—åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œç„¶è€Œåœ¨æœ€æ–°çš„éš¨è¨ªä¸­ï¼Œé€™äº›æ”¹å–„ä¸¦æœªæŒçºŒã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æ¨™è¨˜ï¼ˆå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼‰æœ‰é¡¯è‘—çš„é™ä½æ•ˆæœï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚å„˜ç®¡é€™äº›çµæœæä¾›äº†åˆæ­¥çš„è¦‹è§£ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™å’Œç•°è³ªæ€§ï¼Œç ”ç©¶çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘æœ‰ç ”ç©¶æ¢è¨å®ƒå°ç²¾ç¥å¥åº·çš„å½±éŸ¿ï¼é€™é …ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„æ½›åŠ›ï¼Œæƒ³çœ‹çœ‹å®ƒèƒ½å¦æ”¹å–„æ‚£è€…çš„ç—‡ç‹€ã€‚ç ”ç©¶è€…å€‘åˆ†æäº†369åæ‚£è€…çš„è³‡æ–™ï¼Œé€ééš¨æ©Ÿå°ç…§è©¦é©—ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚\n\nçµæœé¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ åœ¨æ”¹å–„æŸäº›ç—‡ç‹€ä¸Šä¸¦æ²’æœ‰æ˜é¡¯çš„æ•ˆæœï¼Œä½†åœ¨12é€±çš„è§€å¯Ÿä¸­ï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ï¼Œæ•´é«”çš„ç²¾ç¥å¥åº·å¾—åˆ†ä¹Ÿæœ‰æå‡ã€‚ä¸éï¼Œé€™äº›æ”¹å–„åœ¨å¾ŒçºŒçš„éš¨è¨ªä¸­ä¸¦æ²’æœ‰æŒçºŒä¸‹å»ã€‚å€¼å¾—ä¸€æçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼Œä¸¦ä¸”åƒèˆ‡ç ”ç©¶çš„æ‚£è€…åœ¨åœè—¥ç‡ä¸Šä¹Ÿè¼ƒä½ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç™‚æ•ˆä»éœ€é€²ä¸€æ­¥ç ”ç©¶ã€‚\n2. åœ¨çŸ­æœŸå…§ï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ï¼Œä½†æ•ˆæœä¸æŒä¹…ã€‚\n3. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„ä»£è¬æŒ‡æ¨™ï¼Œåœè—¥ç‡è¼ƒä½ã€‚",
    "image_prompt": "Create an infographic illustrating the research study on sulforaphane's effects on schizophrenia. Use a simple and clear flat design style with a white or light-colored background. Include symbols representing broccoli and sulforaphane, simplified illustrations of human subjects, and arrows or flow lines indicating the experimental steps. Highlight a section labeled 'Key Results' showing the minor improvements in negative symptoms and metabolic markers.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å­ç™‡å‰ç—‡ï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å­ç™‡å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„é«˜è¡€å£“ç–¾ç—…ï¼Œå¯èƒ½æœƒå°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„å‚·å®³ï¼Œé€™ä½¿å¾—å®ƒåœ¨æœªä¾†å¯èƒ½æˆç‚ºæ²»ç™‚å­ç™‡å‰ç—‡çš„æ½›åœ¨ç™‚æ³•ã€‚é›–ç„¶ç›®å‰å°šä¸æ¸…æ¥šè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆè½‰ç§»è‡³èƒå…’ï¼Œä½†é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ æœŸé–“å¦‚ä½•åˆ©ç”¨é€™ç¨®æŠ—æ°§åŒ–åŠ‘ä¾†æ”¹å–„æ¯å¬°å¥åº·æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»æƒ…æ³ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¾æ¯è¦ªçš„è¡€æ¶²è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”åœ¨æ¯ä¹³ä¸­æ˜¯å¦èƒ½è¢«æª¢æ¸¬åˆ°ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„å½±éŸ¿ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ä¾æ“šã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8åå¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒæ¥å—å‰–è…¹ç”¢æ‰‹è¡“ã€‚æ‰€æœ‰åƒèˆ‡è€…éƒ½æä¾›äº†æ›¸é¢åŒæ„ã€‚ç ”ç©¶ä¸­ï¼Œå­•å©¦åœ¨æ‰‹è¡“å‰å£æœäº†ä¸€åŠ‘å«æœ‰21æ¯«å…‹è˜¿è””ç¡«ç´ çš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å¾Œæ”¶é›†äº†å¥¹å€‘çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œé‚„æœ‰è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚æ‰‹è¡“å¾Œ2åˆ°4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†äº†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œä»¥é€²è¡Œå¾ŒçºŒåˆ†æã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å¤–å‘¨èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¾†èªªï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªå› ç‚ºæ”å–è˜¿è””ç¡«ç´ è€Œç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„å½±éŸ¿æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å­ç™‡å‰ç—‡ï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å­ç™‡å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„é«˜è¡€å£“ç–¾ç—…ï¼Œå¯èƒ½æœƒå°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„å‚·å®³ï¼Œé€™ä½¿å¾—å®ƒåœ¨æœªä¾†å¯èƒ½æˆç‚ºæ²»ç™‚å­ç™‡å‰ç—‡çš„æ½›åœ¨ç™‚æ³•ã€‚é›–ç„¶ç›®å‰å°šä¸æ¸…æ¥šè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆè½‰ç§»è‡³èƒå…’ï¼Œä½†é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ æœŸé–“å¦‚ä½•åˆ©ç”¨é€™ç¨®æŠ—æ°§åŒ–åŠ‘ä¾†æ”¹å–„æ¯å¬°å¥åº·æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»æƒ…æ³ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¾æ¯è¦ªçš„è¡€æ¶²è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”åœ¨æ¯ä¹³ä¸­æ˜¯å¦èƒ½è¢«æª¢æ¸¬åˆ°ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„å½±éŸ¿ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ä¾æ“šã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8åå¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒæ¥å—å‰–è…¹ç”¢æ‰‹è¡“ã€‚æ‰€æœ‰åƒèˆ‡è€…éƒ½æä¾›äº†æ›¸é¢åŒæ„ã€‚ç ”ç©¶ä¸­ï¼Œå­•å©¦åœ¨æ‰‹è¡“å‰å£æœäº†ä¸€åŠ‘å«æœ‰21æ¯«å…‹è˜¿è””ç¡«ç´ çš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å¾Œæ”¶é›†äº†å¥¹å€‘çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œé‚„æœ‰è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚æ‰‹è¡“å¾Œ2åˆ°4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†äº†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œä»¥é€²è¡Œå¾ŒçºŒåˆ†æã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å¤–å‘¨èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¾†èªªï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªå› ç‚ºæ”å–è˜¿è””ç¡«ç´ è€Œç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„å½±éŸ¿æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯è”¬èœä¸­çš„ä¸€ç¨®æˆåˆ†ï¼Œç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°å­•å©¦çš„å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡ï¼Œç‰¹åˆ¥æ˜¯å­ç™‡å‰ç—‡ï¼Œé€™æ˜¯ä¸€ç¨®åœ¨æ‡·å­•æœŸé–“å¯èƒ½æœƒå°æ¯è¦ªå’Œèƒå…’é€ æˆå½±éŸ¿çš„é«˜è¡€å£“ç–¾ç—…ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¾æ¯è¦ªçš„è¡€æ¶²è½‰ç§»åˆ°èƒå…’ï¼Œé‚„æœ‰æ˜¯å¦èƒ½åœ¨æ¯ä¹³ä¸­æ‰¾åˆ°å®ƒçš„è¹¤è·¡ã€‚  \n\nç‚ºäº†é€²è¡Œé€™é …ç ”ç©¶ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚è¨ˆåŠƒæ¥å—å‰–è…¹ç”¢ã€‚å¥¹å€‘åœ¨æ‰‹è¡“å‰æœç”¨äº†ä¸€åŠ‘å«æœ‰è˜¿è””ç¡«ç´ çš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å¾Œæ”¶é›†äº†è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œé‚„æœ‰è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚  \n\nçµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”çš„è¡€æ¶²ã€è‡å¸¶è¡€å’Œæ¯ä¹³ä¸­éƒ½æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦å®ƒåœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»ï¼é›–ç„¶åœ¨æ‰‹è¡“ç•¶å¤©å­•å©¦çš„è¡€å£“æœ‰äº›è®ŠåŒ–ï¼Œä½†æ•´é«”ä¾†èªªï¼Œæ”å–è˜¿è””ç¡«ç´ ä¸¦æœªé€ æˆé¡¯è‘—å½±éŸ¿ã€‚  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡æœ‰ä¿è­·ä½œç”¨ã€‚  \n2. ç ”ç©¶é¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¾æ¯é«”è½‰ç§»è‡³èƒå…’ã€‚  \n3. æ•´é«”å¥åº·å½±éŸ¿ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ï¼Œä½†çµæœç›¸ç•¶é¼“èˆäººå¿ƒï¼",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of a study on sulforaphane. Include symbols for broccoli or sulforaphane, simplified illustrations of human subjects, and arrows or flow lines to indicate the experimental steps. Add a section labeled 'Main Results' highlighting key findings such as protective effects and any observed changes.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œæ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæµæ²»ç™‚é›–ç„¶èƒ½å¤ æŒ½æ•‘å¿ƒè‡Ÿï¼Œä½†å»å¯èƒ½å¼•ç™¼ç¼ºè¡€å†çŒæµæå‚·ï¼Œé€™ç¨®æå‚·æœƒå°è‡´éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰ç”¢ç”Ÿï¼Œé€²è€Œæå®³å¿ƒè‡Ÿç´°èƒã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ æ¸›å°‘é€™äº›æå‚·çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› å…¶æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å¿ƒè¡€ç®¡ç–¾ç—…çš„æ½›åœ¨é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨æ¸›å°‘å†çŒæµæå‚·æ–¹é¢ã€‚é€™å°æ–¼æ”¹å–„å¿ƒè‡Ÿå¥åº·å’Œé™ä½å¿ƒè¡€ç®¡ç–¾ç—…çš„é¢¨éšªå…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œå†çŒæµæå‚·ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€šéæ”¹è‰¯è˜¿è””ç¡«ç´ çš„çµæ§‹ä¾†æé«˜å…¶ç©©å®šæ€§å’Œæ²»ç™‚æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„æ‡‰ç”¨ã€‚é€™äº›è¡ç”Ÿç‰©çš„æŠ—æ°§åŒ–ç‰¹æ€§å’Œå°æ´»æ€§æ°§çš„æŠ‘åˆ¶ä½œç”¨ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·ï¼Œé€²è€Œæ”¹å–„å¿ƒè‡Ÿçš„æ¢å¾©æƒ…æ³ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼å°‹æ‰¾æœ‰æ•ˆçš„åŒ–åˆç‰©ï¼Œä»¥æ‡‰å°å†çŒæµéç¨‹ä¸­å‡ºç¾çš„æ°§åŒ–å£“åŠ›å’Œç´°èƒæå‚·ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯åŒ–åˆç‰©3gï¼Œä¸¦è©•ä¼°å…¶åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠè…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œé‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†ç©©å®šæ€§æ¸¬è©¦ï¼Œç¢ºä¿é€™äº›åŒ–åˆç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­çš„è€å—æ€§ã€‚é€éåˆ†å­å°æ¥å’ŒADMETåˆ†æï¼Œç ”ç©¶è€…é€²ä¸€æ­¥æ¢è¨äº†é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§åŠå…¶å°Nrf2/Keap1é€šè·¯çš„å½±éŸ¿ï¼Œé€™æœ‰åŠ©æ–¼ç†è§£å…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒçš„ç¼ºæ°§å†çŒæµæå‚·æ–¹é¢å…·æœ‰é¡¯è‘—çš„æ•ˆæœã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å¤ é™ä½æ´»æ€§æ°§çš„æ°´å¹³ï¼Œä¸¦æé«˜æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿï¼Œé¡¯ç¤ºå‡ºå…¶æŠ—æ°§åŒ–çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ‘åˆ¶ç´°èƒå¢æ®–æ–¹é¢çš„æ´»æ€§ä¹Ÿç›¸ç•¶å¼·ï¼Œé¡¯ç¤ºå‡ºæ¯”å¸¸ç”¨çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´é«˜çš„æ•ˆèƒ½ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒåŒ–åˆç‰©3gå¯èƒ½æˆç‚ºæ²»ç™‚å†çŒæµæå‚·åŠç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œæ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæµæ²»ç™‚é›–ç„¶èƒ½å¤ æŒ½æ•‘å¿ƒè‡Ÿï¼Œä½†å»å¯èƒ½å¼•ç™¼ç¼ºè¡€å†çŒæµæå‚·ï¼Œé€™ç¨®æå‚·æœƒå°è‡´éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰ç”¢ç”Ÿï¼Œé€²è€Œæå®³å¿ƒè‡Ÿç´°èƒã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ æ¸›å°‘é€™äº›æå‚·çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› å…¶æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å¿ƒè¡€ç®¡ç–¾ç—…çš„æ½›åœ¨é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨æ¸›å°‘å†çŒæµæå‚·æ–¹é¢ã€‚é€™å°æ–¼æ”¹å–„å¿ƒè‡Ÿå¥åº·å’Œé™ä½å¿ƒè¡€ç®¡ç–¾ç—…çš„é¢¨éšªå…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œå†çŒæµæå‚·ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€šéæ”¹è‰¯è˜¿è””ç¡«ç´ çš„çµæ§‹ä¾†æé«˜å…¶ç©©å®šæ€§å’Œæ²»ç™‚æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„æ‡‰ç”¨ã€‚é€™äº›è¡ç”Ÿç‰©çš„æŠ—æ°§åŒ–ç‰¹æ€§å’Œå°æ´»æ€§æ°§çš„æŠ‘åˆ¶ä½œç”¨ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·ï¼Œé€²è€Œæ”¹å–„å¿ƒè‡Ÿçš„æ¢å¾©æƒ…æ³ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼å°‹æ‰¾æœ‰æ•ˆçš„åŒ–åˆç‰©ï¼Œä»¥æ‡‰å°å†çŒæµéç¨‹ä¸­å‡ºç¾çš„æ°§åŒ–å£“åŠ›å’Œç´°èƒæå‚·ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯åŒ–åˆç‰©3gï¼Œä¸¦è©•ä¼°å…¶åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠè…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œé‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†ç©©å®šæ€§æ¸¬è©¦ï¼Œç¢ºä¿é€™äº›åŒ–åˆç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­çš„è€å—æ€§ã€‚é€éåˆ†å­å°æ¥å’ŒADMETåˆ†æï¼Œç ”ç©¶è€…é€²ä¸€æ­¥æ¢è¨äº†é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§åŠå…¶å°Nrf2/Keap1é€šè·¯çš„å½±éŸ¿ï¼Œé€™æœ‰åŠ©æ–¼ç†è§£å…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒçš„ç¼ºæ°§å†çŒæµæå‚·æ–¹é¢å…·æœ‰é¡¯è‘—çš„æ•ˆæœã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å¤ é™ä½æ´»æ€§æ°§çš„æ°´å¹³ï¼Œä¸¦æé«˜æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿï¼Œé¡¯ç¤ºå‡ºå…¶æŠ—æ°§åŒ–çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ‘åˆ¶ç´°èƒå¢æ®–æ–¹é¢çš„æ´»æ€§ä¹Ÿç›¸ç•¶å¼·ï¼Œé¡¯ç¤ºå‡ºæ¯”å¸¸ç”¨çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´é«˜çš„æ•ˆèƒ½ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒåŒ–åˆç‰©3gå¯èƒ½æˆç‚ºæ²»ç™‚å†çŒæµæå‚·åŠç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿåœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œéœ€è¦ç‰¹åˆ¥çš„ç…§é¡§ï¼Œå› ç‚ºå†çŒæµæ²»ç™‚é›–ç„¶èƒ½æ•‘å¿ƒè‡Ÿï¼Œä½†ä¹Ÿå¯èƒ½é€ æˆå‚·å®³ï¼é€™é …ç ”ç©¶æ­£æ˜¯é‡å°é€™å€‹å•é¡Œï¼Œæ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç‰©è³ªï¼Œçœ‹çœ‹å®ƒèƒ½å¦å¹«åŠ©æˆ‘å€‘çš„å¿ƒè‡Ÿæ›´å¥½åœ°æ¢å¾©ã€‚ç ”ç©¶è€…å€‘åˆæˆäº†ä¸åŒçš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥é—œæ³¨ä¸€ç¨®å«åš3gçš„åŒ–åˆç‰©ï¼Œä¸¦æ¸¬è©¦å®ƒåœ¨å¿ƒè‡Ÿç´°èƒä¸­çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œé€™å€‹3gä¸åƒ…èƒ½é™ä½æœ‰å®³çš„æ´»æ€§æ°§ï¼Œé‚„èƒ½æé«˜æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿï¼Œé€™å°å¿ƒè‡Ÿå¥åº·éå¸¸é‡è¦ï¼æ­¤å¤–ï¼Œå®ƒåœ¨æŠ‘åˆ¶ç´°èƒå¢æ®–æ–¹é¢çš„æ•ˆæœä¹Ÿè¶…éäº†å¸¸è¦‹çš„åŒ–ç™‚è—¥ç‰©ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©æœ‰åŠ©æ–¼æ¸›å°‘å¿ƒè‡Ÿå†çŒæµæå‚·ã€‚  \n2. åŒ–åˆç‰©3gé¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—æ°§åŒ–æ½›åŠ›ã€‚  \n3. 3gåœ¨æŠ‘åˆ¶ç´°èƒå¢æ®–æ–¹é¢çš„æ•ˆæœè¶…éäº†å‚³çµ±åŒ–ç™‚è—¥ç‰©ã€‚",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental methods and key findings of a study on a compound called sulforaphane. Include simplified icons representing broccoli or sulforaphane, experimental subjects like human cells, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results, such as protective effects and changes in reactive oxygen levels.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "æŠ—æ°§åŒ–åŠ‘å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒå€‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œç‰¹åˆ¥æ˜¯åæ‡‰æ€§æ°§ç‰©è³ªï¼ˆROSï¼‰ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¦‚ä½•åˆ©ç”¨å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªä¾†å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›çš„å•Ÿç¤ºï¼Œé€™å¯èƒ½å°æ–¼é é˜²èˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„ç–¾ç—…æœ‰å¹«åŠ©ã€‚é€éäº†è§£é€™äº›å¤©ç„¶ç‰©è³ªçš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„ä¿å¥æ–¹æ³•ï¼Œé€²è€Œæå‡æˆ‘å€‘çš„å¥åº·æ°´å¹³ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜‡å…‹æ—ï¼ˆesculin, ESCï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼Nrf2é€™å€‹è½‰éŒ„å› å­çš„æ¿€æ´»æ•ˆæœã€‚Nrf2æ˜¯ä¸€ç¨®èƒ½å¤ å•Ÿå‹•å¤šç¨®ç´°èƒä¿è­·åŸºå› çš„å› å­ï¼Œå°æŠ—æ°§åŒ–æå‚·ï¼Œå› æ­¤äº†è§£é€™å…©ç¨®ç‰©è³ªçš„å½±éŸ¿å°æ–¼å¥åº·ç ”ç©¶éå¸¸é‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ï¼Œå°‡å…¶åˆ†ç‚ºå¹¾çµ„ï¼Œåˆ†åˆ¥è™•ç†è˜‡å…‹æ—ï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰ï¼Œä¸¦è¨­ç½®å°ç…§çµ„ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬ROSã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€è°·èƒ±ç”˜è‚½Sè½‰ç§»é…¶ï¼ˆGSTï¼‰ã€è°·èƒ±ç”˜è‚½éæ°§åŒ–é…¶ï¼ˆGPxï¼‰ã€éæ°§åŒ–æ°«é…¶ï¼ˆCATï¼‰å’Œé‚„åŸå‹è°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰çš„æ°´å¹³ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†æª¢æ¸¬æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”æƒ…æ³ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜‡å…‹æ—çš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œè˜‡å…‹æ—é‚„å¢å¼·äº†å¤šå€‹æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œè¶…éäº†è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ç ”ç©¶ä¸­é‚„ç™¼ç¾ï¼ŒNrf2åŠå…¶ä»–æŠ—æ°§åŒ–è›‹ç™½åœ¨è˜‡å…‹æ—è™•ç†çµ„ä¸­è¡¨ç¾ä¸Šèª¿ï¼Œä¸¦ä¸”åœ¨å…©çµ„è™•ç†ä¸­éƒ½è§€å¯Ÿåˆ°äº†Nrf2çš„ç´°èƒæ ¸å®šä½ï¼Œé€™è¡¨æ˜Nrf2æˆåŠŸè½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ã€‚é€™äº›çµæœæš—ç¤ºè˜‡å…‹æ—åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼ï¼Œä¸¦ä¸”å¯èƒ½é€šéKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "explanation_zh": "æŠ—æ°§åŒ–åŠ‘å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒå€‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œç‰¹åˆ¥æ˜¯åæ‡‰æ€§æ°§ç‰©è³ªï¼ˆROSï¼‰ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¦‚ä½•åˆ©ç”¨å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªä¾†å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›çš„å•Ÿç¤ºï¼Œé€™å¯èƒ½å°æ–¼é é˜²èˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„ç–¾ç—…æœ‰å¹«åŠ©ã€‚é€éäº†è§£é€™äº›å¤©ç„¶ç‰©è³ªçš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„ä¿å¥æ–¹æ³•ï¼Œé€²è€Œæå‡æˆ‘å€‘çš„å¥åº·æ°´å¹³ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜‡å…‹æ—ï¼ˆesculin, ESCï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼Nrf2é€™å€‹è½‰éŒ„å› å­çš„æ¿€æ´»æ•ˆæœã€‚Nrf2æ˜¯ä¸€ç¨®èƒ½å¤ å•Ÿå‹•å¤šç¨®ç´°èƒä¿è­·åŸºå› çš„å› å­ï¼Œå°æŠ—æ°§åŒ–æå‚·ï¼Œå› æ­¤äº†è§£é€™å…©ç¨®ç‰©è³ªçš„å½±éŸ¿å°æ–¼å¥åº·ç ”ç©¶éå¸¸é‡è¦ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ï¼Œå°‡å…¶åˆ†ç‚ºå¹¾çµ„ï¼Œåˆ†åˆ¥è™•ç†è˜‡å…‹æ—ï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰ï¼Œä¸¦è¨­ç½®å°ç…§çµ„ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬ROSã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€è°·èƒ±ç”˜è‚½Sè½‰ç§»é…¶ï¼ˆGSTï¼‰ã€è°·èƒ±ç”˜è‚½éæ°§åŒ–é…¶ï¼ˆGPxï¼‰ã€éæ°§åŒ–æ°«é…¶ï¼ˆCATï¼‰å’Œé‚„åŸå‹è°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰çš„æ°´å¹³ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†æª¢æ¸¬æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”æƒ…æ³ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜‡å…‹æ—çš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œè˜‡å…‹æ—é‚„å¢å¼·äº†å¤šå€‹æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œè¶…éäº†è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ç ”ç©¶ä¸­é‚„ç™¼ç¾ï¼ŒNrf2åŠå…¶ä»–æŠ—æ°§åŒ–è›‹ç™½åœ¨è˜‡å…‹æ—è™•ç†çµ„ä¸­è¡¨ç¾ä¸Šèª¿ï¼Œä¸¦ä¸”åœ¨å…©çµ„è™•ç†ä¸­éƒ½è§€å¯Ÿåˆ°äº†Nrf2çš„ç´°èƒæ ¸å®šä½ï¼Œé€™è¡¨æ˜Nrf2æˆåŠŸè½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ã€‚é€™äº›çµæœæš—ç¤ºè˜‡å…‹æ—åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼ï¼Œä¸¦ä¸”å¯èƒ½é€šéKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”è£¡æœ‰ä¸€ç¨®å«åšæŠ—æ°§åŒ–åŠ‘çš„è‹±é›„ï¼Œå®ƒå€‘èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—è‡ªç”±åŸºçš„æ”»æ“Šï¼Œä¿è­·ç´°èƒå¥åº·ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œæ¢ç´¢äº†å…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ ï¼Œçœ‹çœ‹å®ƒå€‘åœ¨ä¿è­·ç´°èƒæ–¹é¢çš„è¡¨ç¾ã€‚\n\né€™é …ç ”ç©¶åˆ©ç”¨æ–‘é¦¬é­šå¹¼é«”é€²è¡Œå¯¦é©—ï¼Œå°‡å®ƒå€‘åˆ†æˆå¹¾çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆä¸åŒæ¿ƒåº¦çš„è˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼Œåƒæ˜¯ç´°èƒå…§çš„æ°§åŒ–å£“åŠ›å’ŒæŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œæœ€å¾Œç™¼ç¾è˜‡å…‹æ—ä¸åƒ…èƒ½æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œé‚„èƒ½å¢å¼·ä¸€äº›ä¿è­·åŸºå› çš„è¡¨ç¾ï¼Œç”šè‡³è¶…éäº†è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´äº†è§£å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªå¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„å¥åº·ï¼Œæœªä¾†æˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´å¥½çš„ä¿å¥æ–¹æ³•ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ éƒ½æ˜¯å¤©ç„¶çš„æŠ—æ°§åŒ–åŠ‘ã€‚\n2. è˜‡å…‹æ—åœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºæ›´å¼·çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. é€™äº›ç‰©è³ªå¯èƒ½é€éç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¿è­·ç´°èƒã€‚",
    "image_prompt": "Create an infographic style illustration explaining the experiment and main results of a study comparing two natural compounds, esculin and sulforaphane, in zebrafish larvae. Include simplified icons of broccoli or sulforaphane, zebrafish or cells as experimental subjects, arrows or flow lines to depict the experimental steps, and a section labeled 'Main Results' showing protective effects and changes observed. Use a flat design with a white or light background and soft color palette.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "journal": "British journal of pharmacology",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚çš„é ˜åŸŸã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£åº¦å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å…¶æ‡‰ç”¨ã€‚ç ”ç©¶äººå“¡å¸Œæœ›é€éæ”¹é€²è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œä¾†å¢å¼·å…¶åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„ç™‚æ•ˆï¼Œé€™å°æ–¼æ”¹å–„ç›¸é—œç–¾ç—…çš„æ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨çš„å½±éŸ¿ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ç³–è‹·çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰ä¸­ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•æå‡è˜¿è””ç¡«ç´ åœ¨å…ç–«ç´°èƒä¸­çš„æ•ˆæœï¼Œä¸¦å¸Œæœ›æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—æ…¢æ€§ç™¼ç‚æ‰€å¸¶ä¾†çš„å¥åº·å•é¡Œã€‚é€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼äº†è§£é€™äº›æ–°å‹åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±çš„åæ‡‰ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ï¼Œä»¥æ¨¡æ“¬ç™¼ç‚æƒ…æ³ã€‚ä»–å€‘é–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œä¸¦æ¸¬è©¦å…¶åœ¨é€™äº›ç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ å…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ï¼Œæå‡è˜¿è””ç¡«ç´ çš„æº¶è§£åº¦å’Œç”Ÿç‰©åˆ©ç”¨åº¦ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç³–è‹·åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€éé‡å°p65 NF-ÎºBé€”å¾‘ä¾†é”æˆï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³å°ã€‚é€™äº›åŒ–åˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…è¶Šäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œç‚ºæŠ—ç™¼ç‚ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚çš„é ˜åŸŸã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£åº¦å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å…¶æ‡‰ç”¨ã€‚ç ”ç©¶äººå“¡å¸Œæœ›é€éæ”¹é€²è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œä¾†å¢å¼·å…¶åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„ç™‚æ•ˆï¼Œé€™å°æ–¼æ”¹å–„ç›¸é—œç–¾ç—…çš„æ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨çš„å½±éŸ¿ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ç³–è‹·çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰ä¸­ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•æå‡è˜¿è””ç¡«ç´ åœ¨å…ç–«ç´°èƒä¸­çš„æ•ˆæœï¼Œä¸¦å¸Œæœ›æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—æ…¢æ€§ç™¼ç‚æ‰€å¸¶ä¾†çš„å¥åº·å•é¡Œã€‚é€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼äº†è§£é€™äº›æ–°å‹åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±çš„åæ‡‰ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ï¼Œä»¥æ¨¡æ“¬ç™¼ç‚æƒ…æ³ã€‚ä»–å€‘é–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œä¸¦æ¸¬è©¦å…¶åœ¨é€™äº›ç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ å…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ï¼Œæå‡è˜¿è””ç¡«ç´ çš„æº¶è§£åº¦å’Œç”Ÿç‰©åˆ©ç”¨åº¦ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç³–è‹·åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œç‰¹åˆ¥æ˜¯é€éé‡å°p65 NF-ÎºBé€”å¾‘ä¾†é”æˆï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³å°ã€‚é€™äº›åŒ–åˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…è¶Šäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œç‚ºæŠ—ç™¼ç‚ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢è—è‘—ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç¥å¥‡æˆåˆ†ï¼Œå°æŠ—ç™¼ç‚æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼é€™é …æ–°ç ”ç©¶è®“æˆ‘å€‘æ›´äº†è§£å®ƒçš„é‹ä½œæ–¹å¼ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹å§ï¼\n\nç ”ç©¶äººå“¡å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨é¢å°ç”±ç´°èŒå¼•èµ·çš„ç™¼ç‚åæ‡‰æ™‚çš„è¡¨ç¾ã€‚ä»–å€‘æƒ³çŸ¥é“æ€éº¼æ¨£æ‰èƒ½è®“é€™ç¨®åŒ–åˆç‰©åœ¨å…ç–«ç´°èƒä¸­ç™¼æ®æ›´å¥½çš„æ•ˆæœï¼Œå°æŠ—é‚£äº›æ…¢æ€§ç™¼ç‚å¸¶ä¾†çš„å¥åº·å•é¡Œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œæ¨¡æ“¬ç™¼ç‚ç’°å¢ƒï¼Œä¸¦é–‹ç™¼äº†ä¸€ç¨®æ–°å‹çš„è˜¿è””ç¡«ç´ ç³–è‹·ã€‚ä»–å€‘æ¸¬è©¦äº†é€™ç¨®åŒ–åˆç‰©çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€èƒ½åŠ›ï¼Œå¸Œæœ›èƒ½å…‹æœå‚³çµ±æ–¹æ³•çš„é™åˆ¶ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç³–è‹·åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœéå¸¸é¡¯è‘—ï¼Œå°¤å…¶æ˜¯é€éèª¿ç¯€ä¸€æ¢ç‰¹å®šçš„ä¿¡è™Ÿé€”å¾‘ä¾†é”æˆï¼Œé‚„èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„è€å—æ€§åæ‡‰ï¼Œå¢åŠ æŸäº›æœ‰ç›Šç´°èƒçš„ç”¢ç”Ÿã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ç³–è‹·å°æŠ—ç™¼ç‚æœ‰æ½›åŠ›ã€‚\n2. é€éèª¿ç¯€å…ç–«ç³»çµ±ï¼Œèƒ½å¢å¼·å¥åº·åæ‡‰ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æŠ—ç™¼ç‚æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main findings of a study on sulforaphane glycosides. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like human cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Findings' that highlights protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™¼ç‚ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "journal": "Mikrochimica acta",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·æˆ–ç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨è¨±å¤šæ¤ç‰©ä¸­å­˜åœ¨ï¼Œé€™å¯èƒ½ç‚ºæˆ‘å€‘æä¾›äº†æ–°çš„å¤©ç„¶è³‡æºä¾†é–‹ç™¼å¥åº·ç”¢å“ã€‚é€™äº›åŒ–åˆç‰©å·²çŸ¥å…·æœ‰å¤šç¨®è—¥ç”¨æ•ˆæœï¼Œå› æ­¤äº†è§£å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–é€™äº›æˆåˆ†ï¼Œå¯èƒ½æœƒå°æœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æœ‰é‡è¦å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨å°‹æ‰¾å¤©ç„¶ç™‚æ³•çš„éç¨‹ä¸­ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢ç´¢å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ï¼ˆGlucoraphaninï¼‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦è©•ä¼°å…¶åœ¨éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„å­˜åœ¨æƒ…æ³ï¼Œé€™å°æ–¼æ“´å¤§é€™äº›æœ‰ç›Šæˆåˆ†çš„ä¾†æºå…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è˜¿è””ç¡«ç´ å’ŒGlucoraphaninã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œèƒ½å¤ æœ‰æ•ˆåœ°æª¢æ¸¬åˆ°é€™äº›åŒ–åˆç‰©ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è˜¿è””ç¡«ç´ å’ŒGlucoraphaninï¼Œä¸”åœ¨æ¨£æœ¬ä¸­æ·»åŠ çš„å›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ï¼Œç›¸å°æ¨™æº–åå·®ï¼ˆRSDï¼‰å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆUPLC-MS/MSçš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰è‰¯å¥½çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·æˆ–ç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨è¨±å¤šæ¤ç‰©ä¸­å­˜åœ¨ï¼Œé€™å¯èƒ½ç‚ºæˆ‘å€‘æä¾›äº†æ–°çš„å¤©ç„¶è³‡æºä¾†é–‹ç™¼å¥åº·ç”¢å“ã€‚é€™äº›åŒ–åˆç‰©å·²çŸ¥å…·æœ‰å¤šç¨®è—¥ç”¨æ•ˆæœï¼Œå› æ­¤äº†è§£å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–é€™äº›æˆåˆ†ï¼Œå¯èƒ½æœƒå°æœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æœ‰é‡è¦å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨å°‹æ‰¾å¤©ç„¶ç™‚æ³•çš„éç¨‹ä¸­ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢ç´¢å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ï¼ˆGlucoraphaninï¼‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦è©•ä¼°å…¶åœ¨éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„å­˜åœ¨æƒ…æ³ï¼Œé€™å°æ–¼æ“´å¤§é€™äº›æœ‰ç›Šæˆåˆ†çš„ä¾†æºå…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è˜¿è””ç¡«ç´ å’ŒGlucoraphaninã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œèƒ½å¤ æœ‰æ•ˆåœ°æª¢æ¸¬åˆ°é€™äº›åŒ–åˆç‰©ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è˜¿è””ç¡«ç´ å’ŒGlucoraphaninï¼Œä¸”åœ¨æ¨£æœ¬ä¸­æ·»åŠ çš„å›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ï¼Œç›¸å°æ¨™æº–åå·®ï¼ˆRSDï¼‰å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆUPLC-MS/MSçš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰è‰¯å¥½çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠMikrochimica actaã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ï¼Œç«Ÿç„¶éš±è—è‘—è¨±å¤šæœªè¢«ç™¼æ˜çš„å¥åº·å¯¶è—ï¼é€™æ¬¡çš„ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œå®ƒåœ¨ä¸€äº›éå¯é£Ÿç”¨æ¤ç‰©ä¸­ä¹Ÿèƒ½æ‰¾åˆ°ï¼ç ”ç©¶äººå“¡æƒ³çŸ¥é“ï¼Œæ€éº¼èƒ½æœ‰æ•ˆåœ°å¾é€™äº›æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå®ƒçš„å‰é«”åŒ–åˆç‰©ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘åˆæˆäº†ä¸€ç¨®ç‰¹åˆ¥çš„ææ–™ä¾†å¹«åŠ©æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦ç™¼ç¾å®ƒå€‘åœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©ä¸­éƒ½èƒ½è¢«æª¢æ¸¬åˆ°ï¼Œé€™çœŸæ˜¯å€‹é©šå–œï¼è€Œä¸”ï¼Œé€™ç¨®æ–¹æ³•çš„æª¢æ¸¬æº–ç¢ºç‡éå¸¸é«˜ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘å¯èƒ½èƒ½å¤ å¾é€™äº›æ¤ç‰©ä¸­æå–å‡ºæœ‰ç›Šçš„æˆåˆ†ï¼Œç‚ºå¥åº·ç”¢å“çš„é–‹ç™¼é‹ªè·¯ã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨éå¯é£Ÿç”¨æ¤ç‰©ä¸­å­˜åœ¨ã€‚  \n2. ç ”ç©¶æ–¹æ³•çš„æª¢æ¸¬æº–ç¢ºç‡éå¸¸é«˜ï¼Œå›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ã€‚  \n3. é€™é …ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„å¤©ç„¶å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment method and main results of a study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified figures of experimental subjects like humans or cells, and arrows or flow lines indicating the steps of the experiment. Include a section labeled 'Main Results' that highlights key findings such as the detection of sulforaphane in non-edible plants and high recovery rates.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "journal": "Frontiers in immunology",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„å¤šé‡ä½œç”¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„å¥åº·ä¿ƒé€²æ–¹æ³•ï¼Œä¸¦æ”¹å–„ç™Œç—‡æ‚£è€…çš„æ²»ç™‚æ•ˆæœã€‚é€™ä¸åƒ…æ¶‰åŠé£²é£Ÿçš„é¸æ“‡ï¼Œé‚„åŒ…æ‹¬å¦‚ä½•åˆ©ç”¨é€™äº›å¤©ç„¶æˆåˆ†ä¾†å¢å¼·å‚³çµ±æ²»ç™‚çš„æ•ˆæœï¼Œè®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡é˜²æ²»æœ‰äº†æ–°çš„æ€è€ƒæ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨åŠå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒä»¥åŠå…¶åœ¨äººé«”å…§çš„ç”Ÿç‰©åˆ©ç”¨åº¦ã€‚é€™äº›å•é¡Œçš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„åŸºæœ¬ç”Ÿç‰©å­¸ç‰¹æ€§ï¼Œé‚„èƒ½æ­ç¤ºå…¶åœ¨ç™Œç—‡é˜²æ²»ä¸­çš„å…·é«”æ‡‰ç”¨ï¼Œç‚ºæœªä¾†çš„è‡¨åºŠç ”ç©¶æä¾›åŸºç¤ã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘å¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³å­¸å…¥æ‰‹ï¼Œæ¢è¨äº†è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œä¸¦åˆ†æäº†å…¶åœ¨äººé«”å…§çš„ä½œç”¨ã€‚ç ”ç©¶å°è±¡åŒ…æ‹¬ä¸åŒçš„è…¸é“å¾®ç”Ÿç‰©çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚é€™æ¨£çš„å¤šå±¤æ¬¡ç ”ç©¶æ–¹æ³•ä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºå…¶åœ¨è‡¨åºŠæ‡‰ç”¨æä¾›ç†è«–æ”¯æŒã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±ç™Œç—‡æ²»ç™‚æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚ç ”ç©¶è€…æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶å¯èƒ½æœƒå› å€‹é«”å·®ç•°è€Œæœ‰æ‰€ä¸åŒï¼Œé€™æ„å‘³è‘—åœ¨æœªä¾†çš„æ‡‰ç”¨ä¸­ï¼Œéœ€è¦è€ƒæ…®å€‹é«”çš„åŸºå› èƒŒæ™¯å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆã€‚é€™äº›çµæœç‚ºç²¾æº–ç‡Ÿé¤Šçš„æ¦‚å¿µæä¾›äº†æ”¯æŒï¼Œä¸¦ç‚ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ‡‰ç”¨é–‹å•Ÿäº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„å¤šé‡ä½œç”¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„å¥åº·ä¿ƒé€²æ–¹æ³•ï¼Œä¸¦æ”¹å–„ç™Œç—‡æ‚£è€…çš„æ²»ç™‚æ•ˆæœã€‚é€™ä¸åƒ…æ¶‰åŠé£²é£Ÿçš„é¸æ“‡ï¼Œé‚„åŒ…æ‹¬å¦‚ä½•åˆ©ç”¨é€™äº›å¤©ç„¶æˆåˆ†ä¾†å¢å¼·å‚³çµ±æ²»ç™‚çš„æ•ˆæœï¼Œè®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡é˜²æ²»æœ‰äº†æ–°çš„æ€è€ƒæ–¹å‘ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨åŠå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒä»¥åŠå…¶åœ¨äººé«”å…§çš„ç”Ÿç‰©åˆ©ç”¨åº¦ã€‚é€™äº›å•é¡Œçš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„åŸºæœ¬ç”Ÿç‰©å­¸ç‰¹æ€§ï¼Œé‚„èƒ½æ­ç¤ºå…¶åœ¨ç™Œç—‡é˜²æ²»ä¸­çš„å…·é«”æ‡‰ç”¨ï¼Œç‚ºæœªä¾†çš„è‡¨åºŠç ”ç©¶æä¾›åŸºç¤ã€‚\n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘å¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³å­¸å…¥æ‰‹ï¼Œæ¢è¨äº†è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œä¸¦åˆ†æäº†å…¶åœ¨äººé«”å…§çš„ä½œç”¨ã€‚ç ”ç©¶å°è±¡åŒ…æ‹¬ä¸åŒçš„è…¸é“å¾®ç”Ÿç‰©çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚é€™æ¨£çš„å¤šå±¤æ¬¡ç ”ç©¶æ–¹æ³•ä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºå…¶åœ¨è‡¨åºŠæ‡‰ç”¨æä¾›ç†è«–æ”¯æŒã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±ç™Œç—‡æ²»ç™‚æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚ç ”ç©¶è€…æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶å¯èƒ½æœƒå› å€‹é«”å·®ç•°è€Œæœ‰æ‰€ä¸åŒï¼Œé€™æ„å‘³è‘—åœ¨æœªä¾†çš„æ‡‰ç”¨ä¸­ï¼Œéœ€è¦è€ƒæ…®å€‹é«”çš„åŸºå› èƒŒæ™¯å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆã€‚é€™äº›çµæœç‚ºç²¾æº–ç‡Ÿé¤Šçš„æ¦‚å¿µæä¾›äº†æ”¯æŒï¼Œä¸¦ç‚ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ‡‰ç”¨é–‹å•Ÿäº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in immunologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›æˆåˆ†å¯èƒ½æœƒå¹«åŠ©å°æŠ—ç™Œç—‡ï¼æœ€è¿‘æœ‰ç ”ç©¶èšç„¦åœ¨ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç‰©è³ªï¼Œå®ƒä¾†è‡ªæˆ‘å€‘å¸¸è¦‹çš„åå­—èŠ±ç§‘è”¬èœï¼Œæ¯”å¦‚é’èŠ±æ¤°èœå’Œè˜¿è””ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œç‰¹åˆ¥æ˜¯å®ƒå°ç™Œç—‡å¹¹ç´°èƒå’Œè…«ç˜¤å…ç–«ç’°å¢ƒçš„å½±éŸ¿ã€‚\n\nç ”ç©¶äººå“¡é€éåˆ†ææ¤ç‰©çš„åŸºå› å’Œäººé«”å…§çš„åæ‡‰ï¼Œç™¼ç¾è˜¿è””ç¡«ç´ çš„æ•ˆæœå¯èƒ½æœƒå› äººè€Œç•°ï¼Œé€™æ˜¯å› ç‚ºæ¯å€‹äººçš„åŸºå› å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆä¸åŒã€‚é€™æ¨£çš„ç™¼ç¾ä¸åƒ…è®“æˆ‘å€‘æ›´äº†è§£é€™ç¨®åŒ–åˆç‰©çš„ä½œç”¨ï¼Œé‚„ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\nç°¡å–®ä¾†èªªï¼Œé€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»æ˜¯ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¢å¼·å‚³çµ±ç™Œç—‡æ²»ç™‚çš„æ•ˆæœã€‚\n2. å€‹é«”å·®ç•°æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚\n3. é€™ç‚ºç²¾æº–ç‡Ÿé¤Šçš„æ¦‚å¿µæä¾›äº†æ”¯æŒï¼Œæœªä¾†æˆ–è¨±èƒ½æ›´å¥½åœ°é‹ç”¨é€™ç¨®å¤©ç„¶æˆåˆ†ä¾†é é˜²å’Œæ²»ç™‚ç™Œç—‡ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed in the study. Use a light background with soft colors and a clear, educational style.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "journal": "Biochemical and biophysical research communications",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é é˜²æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½å°èƒƒç™Œçš„é¢¨éšªé™ä½æœ‰æ‰€å¹«åŠ©ï¼Œé›–ç„¶é€™ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éèª¿æ§é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰-å¾®å°RNAï¼ˆmiRNAï¼‰-ä¿¡ä½¿RNAï¼ˆmRNAï¼‰è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œæ³¨ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å…¶åœ¨èƒƒç™Œä¸­çš„è¡¨ç¾åŠå…¶èˆ‡ç™Œç—‡é€²å±•çš„é—œè¯æ€§ã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œä¸¦ç™¼ç¾PSMB8-AS1çš„è¡¨é”æœ‰é¡¯è‘—å·®ç•°ã€‚æ¥è‘—ï¼Œä»–å€‘åˆ©ç”¨TCGAçš„èƒƒç™Œæ•¸æ“šå’Œ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œä¸¦æ¡ç”¨å¤šç¨®å¯¦é©—æ–¹æ³•ï¼ˆå¦‚MTTã€ç´°èƒå…‹éš†å½¢æˆã€åˆ®ç—•ç™’åˆç­‰ï¼‰ä¾†è©•ä¼°PSMB8-AS1çš„åŠŸèƒ½åŠå…¶å°èƒƒç™Œç´°èƒå¢æ®–å’Œé·ç§»çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒPSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡æœ‰é—œã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œé™ä½PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é€éèª¿ç¯€è½‰éŒ„å› å­YY1ä¾†æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”ï¼Œé€²è€Œå½±éŸ¿miR-888-5på’ŒSLC4A7çš„åŠŸèƒ½ã€‚é€™äº›çµæœæš—ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºèƒƒç™Œé é˜²å’Œæ²»ç™‚çš„æ½›åœ¨è—¥ç‰©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é é˜²æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½å°èƒƒç™Œçš„é¢¨éšªé™ä½æœ‰æ‰€å¹«åŠ©ï¼Œé›–ç„¶é€™ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éèª¿æ§é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰-å¾®å°RNAï¼ˆmiRNAï¼‰-ä¿¡ä½¿RNAï¼ˆmRNAï¼‰è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œæ³¨ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å…¶åœ¨èƒƒç™Œä¸­çš„è¡¨ç¾åŠå…¶èˆ‡ç™Œç—‡é€²å±•çš„é—œè¯æ€§ã€‚\n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œä¸¦ç™¼ç¾PSMB8-AS1çš„è¡¨é”æœ‰é¡¯è‘—å·®ç•°ã€‚æ¥è‘—ï¼Œä»–å€‘åˆ©ç”¨TCGAçš„èƒƒç™Œæ•¸æ“šå’Œ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œä¸¦æ¡ç”¨å¤šç¨®å¯¦é©—æ–¹æ³•ï¼ˆå¦‚MTTã€ç´°èƒå…‹éš†å½¢æˆã€åˆ®ç—•ç™’åˆç­‰ï¼‰ä¾†è©•ä¼°PSMB8-AS1çš„åŠŸèƒ½åŠå…¶å°èƒƒç™Œç´°èƒå¢æ®–å’Œé·ç§»çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒPSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡æœ‰é—œã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œé™ä½PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é€éèª¿ç¯€è½‰éŒ„å› å­YY1ä¾†æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”ï¼Œé€²è€Œå½±éŸ¿miR-888-5på’ŒSLC4A7çš„åŠŸèƒ½ã€‚é€™äº›çµæœæš—ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºèƒƒç™Œé é˜²å’Œæ²»ç™‚çš„æ½›åœ¨è—¥ç‰©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiochemical and biophysical research communicationsã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± æƒ³çŸ¥é“æ€éº¼é€éé£²é£Ÿä¾†å¹«åŠ©é é˜²èƒƒç™Œå—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†å¯èƒ½åœ¨é€™æ–¹é¢æœ‰äº›ä½œç”¨å“¦ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®å«åšé•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„åˆ†å­ï¼Œç‰¹åˆ¥æ˜¯PSMB8-AS1ï¼Œé€™åœ¨èƒƒç™Œçš„ç™¼å±•ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨ä¸€äº›é«˜ç§‘æŠ€çš„åˆ†ææ–¹æ³•ï¼Œç™¼ç¾æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒä¸­ï¼ŒPSMB8-AS1çš„è¡¨é”æœ‰æ˜é¡¯çš„è®ŠåŒ–ã€‚\n\næœ€æœ‰è¶£çš„æ˜¯ï¼Œç•¶PSMB8-AS1çš„è¡¨é”é™ä½æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ä¹Ÿéš¨ä¹‹æ¸›å°‘ï¼Œç”šè‡³ä¿ƒé€²äº†ç´°èƒçš„æ­»äº¡ã€‚é€™æ„å‘³è‘—ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€é€™äº›åˆ†å­ä¾†å¹«åŠ©é é˜²èƒƒç™Œã€‚\n\nâœ¨ é€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œé¢¨éšªã€‚\n2. PSMB8-AS1çš„é«˜è¡¨é”èˆ‡ä½ç”Ÿå­˜ç‡æœ‰é—œã€‚\n3. é€²ä¸€æ­¥çš„ç ”ç©¶æœ‰åŠ©æ–¼ç¢ºèªè˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚\n\nè¨˜å¾—å¤šåƒå¥åº·çš„é£Ÿç‰©ï¼Œè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒè‡ªå·±çš„å¥åº·ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experimental process and main findings of the study on sulforaphane and gastric cancer. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like human cells), arrows or flow lines showing the experimental steps, and a section clearly labeled 'Main Findings' that highlights protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  },
  {
    "id": "41235157",
    "title_en": "Novel magnolol-sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization.",
    "pub_date": "2025 Oct",
    "journal": "RSC medicinal chemistry",
    "abstract_en": "The natural product-based hybrid strategy is a promising approach for innovative drug discovery. Leveraging the privileged architecture of sulforaphane-a prominent anticancer natural product-we engineered a novel library of magnolol-sulforaphane molecular hybrids for antitumor evaluation through a concise synthetic strategy for the pharmacophore of sulforaphane (SFN), culminating in the identification of CTNPC8 as a promising anticancer compound. Notably, CTNPC8 not only displays exceptional broad-spectrum anticancer activity with potency surpassing both parent compounds and cisplatin, but also exhibits potent <i>in vitro</i> efficacy against the challenging nasopharyngeal carcinoma (NPC) cell model. Mechanistic studies in nasopharyngeal carcinoma models reveal that CTNPC8 triggers mitochondrial-mediated apoptosis through regulating ROS generation and induces G<sub>2</sub>/M phase arrest. Transcriptomic profiling coupled with validation experiments reveals that CTNPC8 exerts its anti-NPC activity primarily by modulating the Akt/mTOR pathway. The present study provided a valuable strategy for discovering new antitumor agents through hybrid molecular design, nominating CTNPC8 as a promising hit compound for anti-NPC research.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å¹«åŠ©ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼åˆ©ç”¨å¤©ç„¶ç”¢å“ä¾†é–‹ç™¼æ–°è—¥ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç™Œç—‡çš„æ²»ç™‚ã€‚é€™ç¨®æ–¹æ³•ä¸åƒ…èƒ½å¤ å°‹æ‰¾æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°é›£æ²»çš„ç™Œç—‡é¡å‹æ™‚ï¼Œä¾‹å¦‚é¼»å’½ç™Œã€‚é€éé€™ç¨®å‰µæ–°çš„ç­–ç•¥ï¼Œæˆ–è¨±èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œæ”¹å–„ç—…æ‚£çš„ç”Ÿæ´»å“è³ªå’Œé å¾Œã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼ä¸€ç¨®æ–°çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œç‰¹åˆ¥é‡å°é¼»å’½ç™Œã€‚ç ”ç©¶è€…å€‘åˆ©ç”¨ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç”¢å“ï¼Œä¸¦å°‡å…¶èˆ‡å¦ä¸€ç¨®åŒ–åˆç‰©çµåˆï¼Œå‰µé€ å‡ºä¸€ç¨®æ–°çš„åˆ†å­æ··åˆç‰©ï¼Œç›®çš„æ˜¯è©•ä¼°å…¶æŠ—è…«ç˜¤çš„æ•ˆæœã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œå¿ƒæ–°åŒ–åˆç‰©çš„æŠ—ç™Œæ´»æ€§ï¼Œé‚„æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ï¼Œè©¦åœ–äº†è§£å®ƒæ˜¯å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘åˆæˆäº†ä¸€ç³»åˆ—çš„è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©çš„æ··åˆç‰©ï¼Œä¸¦å°é€™äº›æ–°åŒ–åˆç‰©é€²è¡ŒæŠ—è…«ç˜¤è©•ä¼°ã€‚ç ”ç©¶ä¸»è¦é‡å°é¼»å’½ç™Œç´°èƒæ¨¡å‹ï¼Œé€éç´°èƒå¯¦é©—ä¾†æ¸¬è©¦é€™äº›åŒ–åˆç‰©çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†æ©Ÿåˆ¶ç ”ç©¶ï¼Œä»¥äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éè·¯å¾‘ï¼Œç‰¹åˆ¥æ˜¯èˆ‡ç´°èƒæ­»äº¡å’Œç”Ÿé•·ç›¸é—œçš„è·¯å¾‘ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼ŒCTNPC8é€™ç¨®æ–°åŒ–åˆç‰©åœ¨æŠ—ç™Œæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—é¼»å’½ç™Œæ™‚ï¼Œå…¶æ•ˆæœè¶…éäº†åŸå§‹çš„å…©ç¨®åŒ–åˆç‰©å’Œé †é‰‘ã€‚CTNPC8èƒ½å¤ èª˜å°ç´°èƒå‡‹äº¡ï¼Œä¸¦é€šéèª¿ç¯€æ´»æ€§æ°§çš„ç”Ÿæˆä¾†å½±éŸ¿ç´°èƒé€±æœŸï¼Œå°è‡´ç´°èƒåœæ»¯åœ¨G2/Méšæ®µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾CTNPC8ä¸»è¦é€šéèª¿ç¯€Akt/mTORä¿¡è™Ÿé€šè·¯ä¾†ç™¼æ®å…¶æŠ—é¼»å’½ç™Œçš„ä½œç”¨ã€‚é€™äº›çµæœé¡¯ç¤ºCTNPC8æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„æŠ—è…«ç˜¤åŒ–åˆç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å¹«åŠ©ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼åˆ©ç”¨å¤©ç„¶ç”¢å“ä¾†é–‹ç™¼æ–°è—¥ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç™Œç—‡çš„æ²»ç™‚ã€‚é€™ç¨®æ–¹æ³•ä¸åƒ…èƒ½å¤ å°‹æ‰¾æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°é›£æ²»çš„ç™Œç—‡é¡å‹æ™‚ï¼Œä¾‹å¦‚é¼»å’½ç™Œã€‚é€éé€™ç¨®å‰µæ–°çš„ç­–ç•¥ï¼Œæˆ–è¨±èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œæ”¹å–„ç—…æ‚£çš„ç”Ÿæ´»å“è³ªå’Œé å¾Œã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼ä¸€ç¨®æ–°çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œç‰¹åˆ¥é‡å°é¼»å’½ç™Œã€‚ç ”ç©¶è€…å€‘åˆ©ç”¨ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç”¢å“ï¼Œä¸¦å°‡å…¶èˆ‡å¦ä¸€ç¨®åŒ–åˆç‰©çµåˆï¼Œå‰µé€ å‡ºä¸€ç¨®æ–°çš„åˆ†å­æ··åˆç‰©ï¼Œç›®çš„æ˜¯è©•ä¼°å…¶æŠ—è…«ç˜¤çš„æ•ˆæœã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œå¿ƒæ–°åŒ–åˆç‰©çš„æŠ—ç™Œæ´»æ€§ï¼Œé‚„æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ï¼Œè©¦åœ–äº†è§£å®ƒæ˜¯å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘åˆæˆäº†ä¸€ç³»åˆ—çš„è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©çš„æ··åˆç‰©ï¼Œä¸¦å°é€™äº›æ–°åŒ–åˆç‰©é€²è¡ŒæŠ—è…«ç˜¤è©•ä¼°ã€‚ç ”ç©¶ä¸»è¦é‡å°é¼»å’½ç™Œç´°èƒæ¨¡å‹ï¼Œé€éç´°èƒå¯¦é©—ä¾†æ¸¬è©¦é€™äº›åŒ–åˆç‰©çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†æ©Ÿåˆ¶ç ”ç©¶ï¼Œä»¥äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éè·¯å¾‘ï¼Œç‰¹åˆ¥æ˜¯èˆ‡ç´°èƒæ­»äº¡å’Œç”Ÿé•·ç›¸é—œçš„è·¯å¾‘ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾æ˜¯ï¼ŒCTNPC8é€™ç¨®æ–°åŒ–åˆç‰©åœ¨æŠ—ç™Œæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—é¼»å’½ç™Œæ™‚ï¼Œå…¶æ•ˆæœè¶…éäº†åŸå§‹çš„å…©ç¨®åŒ–åˆç‰©å’Œé †é‰‘ã€‚CTNPC8èƒ½å¤ èª˜å°ç´°èƒå‡‹äº¡ï¼Œä¸¦é€šéèª¿ç¯€æ´»æ€§æ°§çš„ç”Ÿæˆä¾†å½±éŸ¿ç´°èƒé€±æœŸï¼Œå°è‡´ç´°èƒåœæ»¯åœ¨G2/Méšæ®µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾CTNPC8ä¸»è¦é€šéèª¿ç¯€Akt/mTORä¿¡è™Ÿé€šè·¯ä¾†ç™¼æ®å…¶æŠ—é¼»å’½ç™Œçš„ä½œç”¨ã€‚é€™äº›çµæœé¡¯ç¤ºCTNPC8æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„æŠ—è…«ç˜¤åŒ–åˆç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠRSC medicinal chemistryã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½æœƒæˆç‚ºæœªä¾†æŠ—ç™Œè—¥ç‰©çš„é—œéµï¼é€™æ¬¡çš„ç ”ç©¶å°±èšç„¦åœ¨ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œç ”ç©¶è€…å€‘å¸Œæœ›èƒ½æ‰¾åˆ°å°æŠ—é¼»å’½ç™Œçš„æ–°æ–¹æ³•ã€‚\n\nä»–å€‘çš„åšæ³•æ˜¯å°‡è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©çµåˆï¼Œå‰µé€ å‡ºä¸€ç¨®æ–°çš„æ··åˆç‰©ï¼Œä¸¦æ¸¬è©¦å®ƒçš„æŠ—è…«ç˜¤æ•ˆæœã€‚åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘ä¸»è¦é‡å°é¼»å’½ç™Œç´°èƒé€²è¡Œäº†è©•ä¼°ï¼Œä¸¦æ¢ç´¢é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚\n\næœ€ä»¤äººèˆˆå¥®çš„ç™¼ç¾æ˜¯ï¼Œé€™ç¨®æ–°çš„åŒ–åˆç‰©CTNPC8åœ¨æŠ—ç™Œæ–¹é¢è¡¨ç¾å„ªç•°ï¼Œç‰¹åˆ¥æ˜¯å°é¼»å’½ç™Œçš„æ•ˆæœè¶…éäº†å…¶ä»–å·²çŸ¥çš„è—¥ç‰©ï¼CTNPC8èƒ½å¤ èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦å½±éŸ¿ç´°èƒçš„ç”Ÿé•·é€±æœŸï¼Œé€™è®“å®ƒæˆç‚ºä¸€å€‹æœ‰æ½›åŠ›çš„æŠ—è…«ç˜¤åŒ–åˆç‰©ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æ˜¯æœªä¾†æŠ—ç™Œè—¥ç‰©çš„é—œéµæˆåˆ†ã€‚  \n2. æ–°åŒ–åˆç‰©CTNPC8åœ¨å°æŠ—é¼»å’½ç™Œæ–¹é¢è¡¨ç¾å„ªç•°ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯å’Œå¸Œæœ›ï¼",
    "image_prompt": "Create an informative infographic that explains the experimental process and main results of a study on a natural compound called sulforaphane. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines showing the experimental steps, and a section clearly labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "é¼»å’½ç™Œ Nasopharyngeal Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41235157/"
  },
  {
    "id": "41181585",
    "title_en": "Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "Acute liver injury (ALI) caused by sepsis is a fatal disease with a high mortality rate and poor prognosis. Sulforaphane (SFN) is a natural isothiocyanate that has robust antioxidant and anti-inflammatory properties. The aim of this study was to identify the pharmacological effects and therapeutic mechanisms of SFN in lipopolysaccharide (LPS)-induced ALI. The role of SFN in ALI was investigated using a mouse model of LPS-induced ALI. Briefly, eighteen mice were divided into three groups: control, LPS, and LPS + SFN, which were intraperitoneally injected for 2Â days before LPS treatment. 24Â h after the LPS injection, blood and liver tissues were collected for further analysis. The hematoxylin and eosin (HE) staining showed a lot of visible necrosis areas, inflammatory cell infiltration, and congestion in liver. Meanwhile, Ly6G and F4/80 staining showed increased infiltration of neutrophils and macrophages in liver, these results indicated that LPS induced sever ALI. As inflammatory response plays a vital role in the pathogenesis of LPS-induced ALI, we detected the occurrence of pyroptosis in liver by ribonucleic acid (RNA) sequencing. The results showed that pyroptosis was significantly promoted by LPS, as indicated by gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses, revealing the activation of pyroptosis, interleukin (IL)-1 production, IL-18 production, and inflammatory signaling pathways. Then, we explored the effect of SFN on LPS-induced ALI. The results showed that SFN obviously reduced LPS-induced plasma alanine aminotransferase and aspartate aminotransferase level, pathological injuries and TdT-mediated dUTP nick-end labeling (TUNEL) positive cells, indicating protective effect of SFN on ALI. Furthermore, SFN also showed robust effect on LPS-induced inflammatory response in liver, as reflected by suppressing the infiltration of neutrophils and macrophages, and downregulating mRNA levels of C-X-C motif chemokine ligand 9, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-Î± in liver of LPS treated mice. Furthermore, SFN blocked hepatocyte pyroptosis, and suppressed plasma IL-1Î² and IL-18 levels of LPS treated mice. Mechanistically, SFN selectively activated nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling to mediate pyroptotic cell death. SFN also reversed the inhibited superoxide dismutase activity and induced malondialdehyde content in liver of LPS exposed mice. SFN ameliorated liver injury and inflammation during LPS-induced ALI by suppressing hepatocyte pyroptosis via the activation of Nrf2/HO-1 signaling. This study provides new evidence for the potential treatment of ALI with SFN.",
    "para1": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç–¾ç—…ä¸­çš„æ½›åœ¨æ²»ç™‚æ•ˆæœï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ï¼Œé€™å°æ–¼æ”¹å–„è‚è‡Ÿå¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ¸›å°‘æ€¥æ€§è‚æå‚·çš„é¢¨éšªï¼Œä¸¦æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ å°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†æ•ˆæ‡‰åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ¸›è¼•è‚è‡Ÿçš„æå‚·ï¼Œä¸¦æ¢è¨å…¶åœ¨ç‚ç—‡åæ‡‰ä¸­çš„ä½œç”¨ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„æ²»ç™‚ç­–ç•¥ä»¥æ‡‰å°æ€¥æ€§è‚æå‚·çš„æŒ‘æˆ°å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ç ”ç©¶è€…å°‡åå…«éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œé€éçµ„ç¹”æŸ“è‰²å’ŒåŸºå› æ¸¬åºä¾†è©•ä¼°è‚è‡Ÿçš„æå‚·ç¨‹åº¦åŠç‚ç—‡åæ‡‰ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSå¼•èµ·çš„è‚è‡Ÿæå‚·æŒ‡æ¨™ï¼Œå¦‚è¡€æ¼¿ä¸­çš„ä¸™æ°¨é…¸æ°¨åŸºè½‰ç§»é…¶å’Œå¤©å†¬æ°¨é…¸æ°¨åŸºè½‰ç§»é…¶æ°´å¹³ï¼Œä¸¦æ¸›å°‘è‚è‡Ÿçš„ç—…ç†æå‚·å’Œç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶LPSå¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦èª¿ç¯€å¤šç¨®ç‚ç—‡ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œå°æ–¼æ€¥æ€§è‚æå‚·çš„æ²»ç™‚æä¾›äº†æ–°çš„è­‰æ“šã€‚",
    "explanation_zh": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç–¾ç—…ä¸­çš„æ½›åœ¨æ²»ç™‚æ•ˆæœï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ï¼Œé€™å°æ–¼æ”¹å–„è‚è‡Ÿå¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ¸›å°‘æ€¥æ€§è‚æå‚·çš„é¢¨éšªï¼Œä¸¦æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ å°ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†æ•ˆæ‡‰åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ¸›è¼•è‚è‡Ÿçš„æå‚·ï¼Œä¸¦æ¢è¨å…¶åœ¨ç‚ç—‡åæ‡‰ä¸­çš„ä½œç”¨ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„æ²»ç™‚ç­–ç•¥ä»¥æ‡‰å°æ€¥æ€§è‚æå‚·çš„æŒ‘æˆ°å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ç ”ç©¶è€…å°‡åå…«éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œé€éçµ„ç¹”æŸ“è‰²å’ŒåŸºå› æ¸¬åºä¾†è©•ä¼°è‚è‡Ÿçš„æå‚·ç¨‹åº¦åŠç‚ç—‡åæ‡‰ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSå¼•èµ·çš„è‚è‡Ÿæå‚·æŒ‡æ¨™ï¼Œå¦‚è¡€æ¼¿ä¸­çš„ä¸™æ°¨é…¸æ°¨åŸºè½‰ç§»é…¶å’Œå¤©å†¬æ°¨é…¸æ°¨åŸºè½‰ç§»é…¶æ°´å¹³ï¼Œä¸¦æ¸›å°‘è‚è‡Ÿçš„ç—…ç†æå‚·å’Œç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶LPSå¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦èª¿ç¯€å¤šç¨®ç‚ç—‡ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œå°æ–¼æ€¥æ€§è‚æå‚·çš„æ²»ç™‚æä¾›äº†æ–°çš„è­‰æ“šã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯æˆ‘å€‘é¤æ¡Œä¸Šçš„ç¾å‘³ï¼Œå®ƒè£¡é¢é‚„è—è‘—å°è‚è‡Ÿå¥åº·çš„æ½›åœ¨å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦åœ¨è˜¿è””ç¡«ç´ ï¼Œé€™æ˜¯ä¸€ç¨®å¾è˜¿è””ä¸­æå–çš„å¤©ç„¶æˆåˆ†ï¼Œç§‘å­¸å®¶å€‘ç™¼ç¾å®ƒå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ€¥æ€§è‚æå‚·çš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å°æŠ—ç”±ç´°èŒå¼•èµ·çš„è‚è‡Ÿæå‚·ã€‚ç ”ç©¶è€…å€‘ç”¨å°é¼ ä¾†é€²è¡Œå¯¦é©—ï¼Œå°‡å®ƒå€‘åˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆä¸åŒçš„è™•ç†æ–¹å¼ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„è‚è‡Ÿç‹€æ³ã€‚åœ¨LPSï¼ˆç´°èŒæˆåˆ†ï¼‰å¼•èµ·çš„æå‚·å¾Œï¼Œç ”ç©¶è€…å€‘ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½è‚è‡Ÿæå‚·æŒ‡æ¨™ï¼Œä¸¦æ¸›å°‘ç‚ç—‡åæ‡‰ã€‚\n\né€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»æŸäº›ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œå°æ–¼æ”¹å–„æ€¥æ€§è‚æå‚·çš„æƒ…æ³æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n- è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚è‡Ÿï¼Œæ¸›å°‘æå‚·ã€‚\n- å®ƒèƒ½é™ä½ç‚ç—‡åæ‡‰ï¼Œè®“è‚è‡Ÿæ›´å¥åº·ã€‚\n- é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a simple and informative illustration explaining the experiment and main results of a study on the effects of sulforaphane from radishes on acute liver injury. The style should be flat design with a white or light-colored background and soft colors. Include symbols for broccoli or radish to represent sulforaphane, simplified icons of experimental subjects like mice or cells, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§è‚æå‚· Acute Liver Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41181585/"
  }
]